2021


  1. Kayser S, Hills RK, Langova R, Kramer M, Guijarro F, Sustkova Z, Estey EH, Shaw CM, Rá?il Z, Mayer J, Zak P, Baer MR, Brunner AM, Szotkowski T, Cetkovsky P, Grimwade D, Walter RB, Burnett AK, Ho AD, Ehninger G, Müller-Tidow C, Platzbecker U, Thiede C, Röllig C, Schulz A, Warsow G, Brors B, Esteve J, Russell NH, Schlenk RF, Levis MJ (2021). Characteristics and outcome of patients with acute myeloid leukaemia and t(8;16)(p11;p13): results from an International Collaborative Study. Br J Haematol, 192(5), 832-842.
     
  2. Steensma DP, Fenaux P, Van Eygen K, Raza A, Santini V, Germing U, Font P, Diez-Campelo M, Thepot S, Vellenga E, Patnaik MM, Jang JH, Varsos H, Bussolari J, Rose E, Sherman L, Sun L, Wan Y, Dougherty S, Huang F, Feller F, Rizo A, Platzbecker U (2021). Imetelstat Achieves Meaningful and Durable Transfusion Independence in High Transfusion-Burden Patients With Lower-Risk Myelodysplastic Syndromes in a Phase II Study. J Clin Oncol, 39(1), 48-56.
     
  3. Franke GN, Lückemeier P, Platzbecker U (2021). Allogeneic Stem-Cell Transplantation in Patients With Myelodysplastic Syndromes and Prevention of Relapse. Clin Lymphoma Myeloma Leuk, 21(1), 1-7.
     
  4. Heidel FH, Platzbecker U (2021). The Genomic Landscape of Myeloid Malignancies: Options for Pan-myeloid Therapies? Hemasphere, 5(3), 537.
     
  5. Brauer D, Backhaus D, Pointner R, Vucinic V, Niederwieser D, Platzbecker U, Schwind S, Jentzsch M (2021). Nutritional Status at Diagnosis and Pre-transplant Weight Loss Impact Outcomes of Acute Myeloid Leukemia Patients Following Allogeneic Stem Cell Transplantation. Hemasphere, 5(3), 532.
     
  6. Wang SY, Thomassen K, Kurch L, Opitz S, Franke GN, Bach E, Platzbecker U, Kayser S (2021). Combination of Tagraxofusp and Azacitidine Is an Effective Option for Relapsed Blastic Plasmacytoid Dendritic Cell Neoplasm After Allogeneic Hematopoietic Stem-Cell Transplantation. Clin Lymphoma Myeloma Leuk, (), 52-60.
     
  7. Panitz N, Gerhardt K, Becker C, Schleife H, Bach E, Opitz S, Schaudinn A, Platzbecker U, Kayser S (2021). Two rare cases of bronchus-associated lymphoid tissue lymphoma successfully treated with rituximab-bendamustine. Clin Case Rep, 9(8), 557.
     
  8. Jentzsch M, Grimm J, Bill M, Brauer D, Backhaus D, Schulz J, Goldmann K, Niederwieser D, Platzbecker U, Schwind S (2021). Prognostic relevance of remission and measurable residual disease status in AML patients prior to reduced intensity or non-myeloablative allogeneic stem cell transplantation. Blood Cancer J, 11(4), 80.
     
  9. Platzbecker U, Kubasch AS, Homer-Bouthiette C, Prebet T (2021). Current challenges and unmet medical needs in myelodysplastic syndromes. Leukemia, 35(8), 2182-2198.
     
  10. Kubasch AS, Fenaux P, Platzbecker U (2021). Development of luspatercept to treat ineffective erythropoiesis. Blood Adv, 5(5), 1565-1575.
     
  11. Nagler A, Dholaria B, Labopin M, Bruno B, Rambaldi A, Pioltelli P, La Nasa G, Socié G, Mielke S, Ruggeri M, Saccardi R, Franke GN, Finke J, Savani BN, Ruggeri A, Mohty M (2021). The outcome of two or more HLA loci mismatched unrelated donor hematopoietic cell transplantation for acute leukemia: an ALWP of the EBMT study. Bone Marrow Transplant, 56(1), 20-29.
     
  12. Montesinos P, Roboz GJ, Bulabois CE, Subklewe M, Platzbecker U, Ofran Y, Papayannidis C, Wierzbowska A, Shin HJ, Doronin V, Deneberg S, Yeh SP, Ozcan MA, Knapper S, Cortes J, Pollyea DA, Ossenkoppele G, Giralt S, Döhner H, Heuser M, Xiu L, Singh I, Huang F, Larsen JS, Wei AH (2021). Safety and efficacy of talacotuzumab plus decitabine or decitabine alone in patients with acute myeloid leukemia not eligible for chemotherapy: results from a multicenter, randomized, phase 2/3 study. Leukemia, 35(1), 62-74.
     
  13. Verstovsek S, Chen CC, Egyed M, Ellis M, Fox L, Goh YT, Gupta V, Harrison C, Kiladjian JJ, Lazaroiu MC, Mead A, McLornan D, McMullin MF, Oh ST, Perkins A, Platzbecker U, Scheid C, Vannucchi A, Yoon SS, Kowalski MM, Mesa RA (2021). MOMENTUM: momelotinib vs danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemic. Future Oncol, (), 10-20.
     
  14. Hannemann A, Nauck M, Völzke H, Weidner H, Platzbecker U, Hofbauer LC, Rauner M, Baschant U (2021). Interactions of Anemia, FGF-23, and Bone in Healthy Adults-Results From the Study of Health in Pomerania (SHIP). J Clin Endocrinol Metab, 106(1), 288-299.
     
  15. Middeke JM, Teipel R, Röllig C, Stasik S, Zebisch A, Sill H, Kramer M, Scholl S, Hochhaus A, Jost E, Brümmendorf TH, Naumann R, Steffen B, Serve H, Altmann H, Kunzmann V, Einsele H, Parmentier S, Schaich M, Burchert A, Neubauer A, Schliemann C, Berdel WE, Sockel K, Stölzel F, Platzbecker U, Ehninger G, Bornhäuser M, Schetelig J, Thiede C (2021). Decitabine treatment in 311 patients with acute myeloid leukemia: outcome and impact of TP53 mutations - a registry based analysis. Leuk Lymphoma, (), 1-15.
     
  16. Holzhey T, Pönisch W, Wang SY, Holzvogt M, Holzvogt B, Andrea M, Zehrfeld T, Hammerschmidt D, Hoffmann FA, Becker C, Schwarzer A, Schwarz M, Schönfelder-Fricke U, Edelmann T, Braunert L, Franke GN, Jentzsch M, Schwind S, Bill M, Grimm J, Remane Y, Platzbecker U, Scholz M (2021). Prognostic impact of rapid reduction of involved free light chains in multiple myeloma patients under first-line treatment with Bendamustine, Prednisone, and Bortezomib (BPV). J Cancer Res Clin Oncol, (), 432-480.
     
  17. Bersanelli M, Travaglino E, Meggendorfer M, Matteuzzi T, Sala C, Mosca E, Chiereghin C, Di Nanni N, Gnocchi M, Zampini M, Rossi M, Maggioni G, Termanini A, Angelucci E, Bernardi M, Borin L, Bruno B, Bonifazi F, Santini V, Bacigalupo A, Voso MT, Oliva E, Riva M, Ubezio M, Morabito L, Campagna A, Saitta C, Savevski V, Giampieri E, Remondini D, Passamonti F, Ciceri F, Bolli N, Rambaldi A, Kern W, Kordasti S, Sole F, Palomo L, Sanz G, Santoro A, Platzbecker U, Fenaux P, Milanesi L, Haferlach T, Cast (2021). Classification and Personalized Prognostic Assessment on the Basis of Clinical and Genomic Features in Myelodysplastic Syndromes. J Clin Oncol, (), 59-65.
     
  18. Röllig C, Serve H, Noppeney R, Hanoun M, Krug U, Baldus CD, Brandts CH, Kunzmann V, Einsele H, Krämer A, Müller-Tidow C, Schäfer-Eckart K, Neubauer A, Burchert A, Giagounidis A, Krause SW, Mackensen A, Aulitzky W, Herbst R, Hänel M, Frickhofen N, Kullmer J, Kaiser U, Kiani A, Link H, Geer T, Reichle A, Junghanß C, Repp R, Meinhardt A, Dürk H, Klut IM, Bornhäuser M, Schaich M, Parmentier S, Görner M, Thiede C, von Bonin M, Platzbecker U, Schetelig J, Kramer M, Berdel WE, Ehninger G (2021). Sorafenib or placebo in patients with newly diagnosed acute myeloid leukaemia: long-term follow-up of the randomized controlled SORAML trial. Leukemia, (), 38-45.
     
  19. Blache U, Weiss R, Boldt A, Kapinsky M, Blaudszun AR, Quaiser A, Pohl A, Miloud T, Burgaud M, Vucinic V, Platzbecker U, Sack U, Fricke S, Koehl U (2021). Advanced Flow Cytometry Assays for Immune Monitoring of CAR-T Cell Applications. Front Immunol, 12(), 658314.
     
  20. Stomper J, Meier R, Ma T, Pfeifer D, Ihorst G, Blagitko-Dorfs N, Greve G, Zimmer D, Platzbecker U, Hagemeijer A, Schmitt-Graeff I, Lübbert M (2021). Correction to: Integrative study of EZH2 mutational status, copy number, protein expression and H3K27 trimethylation in AML/MDS patients. Clin Epigenetics, 13(1), 94.
     
  21. Stomper J, Meier R, Ma T, Pfeifer D, Ihorst G, Blagitko-Dorfs N, Greve G, Zimmer D, Platzbecker U, Hagemeijer A, Schmitt-Graeff I, Lübbert M (2021). Integrative study of EZH2 mutational status, copy number, protein expression and H3K27 trimethylation in AML/MDS patients. Clin Epigenetics, 13(1), 77.
     
  22. Eckardt JN, Stasik S, Kramer M, Röllig C, Krämer A, Scholl S, Hochhaus A, Crysandt M, Brümmendorf TH, Naumann R, Steffen B, Kunzmann V, Einsele H, Schaich M, Burchert A, Neubauer A, Schäfer-Eckart K, Schliemann C, Krause SW, Herbst R, Hänel M, Frickhofen N, Noppeney R, Kaiser U, Baldus CD, Kaufmann M, Rácil Z, Platzbecker U, Berdel WE, Mayer J, Serve H, Müller-Tidow C, Ehninger G, Stölzel F, Kroschinsky F, Schetelig J, Bornhäuser M, Thiede C, Middeke JM (2021). Loss-of-Function Mutations of BCOR Are an Independent Marker of Adverse Outcomes in Intensively Treated Patients with Acute Myeloid Leukemia. Cancers (Basel), 13(9), 2095.
     
  23. Ruhnke L, Stölzel F, Wagenführ L, Altmann H, Platzbecker U, Herold S, Rump A, Schröck E, Bornhäuser M, Schetelig J, von Bonin M (2021). Case Report: ANXA2 Associated Life-Threatening Coagulopathy With Hyperfibrinolysis in a Patient With Non-APL Acute Myeloid Leukemia. Front Oncol, 11(), 666014.
     
  24. Gagelmann N, Badbaran A, Beelen DW, Salit RB, Stölzel F, Rautenberg C, Becker H, Radujkovic A, Panagiota V, Bogdanov R, Christopeit M, Park Y, Nibourel O, Luft T, Koldehoff M, Corsten M, Heuser M, Finke J, Kobbe G, Platzbecker U, Robin M, Scott BL, Kröger N (2021). A prognostic score including mutation profile and clinical features for patients with CMML undergoing stem cell transplantation. Blood Adv, 5(6), 1760-1769.
     


  25. 2020


  26. Kubasch AS, Franke GN, Aldaoud A, Weibl K, Jentzsch M, Sabri O, Horny HP, Fend F, Behre G, Platzbecker U, Vucinic V (2020). Allogeneic Hematopoietic Stem Cell Transplantation in a Rare Case of Tonsillar Mast Cell Sarcoma. Front Oncol, 10, 219.
     
  27. Jentzsch M, Grimm J, Bill M, Goldmann K, Schulz J, Niederwieser D, Platzbecker U, Schwind S (2020). Outcomes of Older Patients with NPM1 Mutated and FLT3-ITD Negative Acute Myeloid Leukemia Receiving Allogeneic Transplantation. Hemasphere, 4(1), e326-.
     
  28. Schwind S, Jentzsch M, Bach E, Stasik S, Thiede C, Platzbecker U (2020). Use of Minimal Residual Disease in Acute Myeloid Leukemia Therapy. Curr Treat Options Oncol, 21(1), 8-.
     
  29. Kubasch AS, Schulze F, Giagounidis A, Gotze KS, Kronke J, Sockel K, Middeke JM, Chermat F, Gloaguen S, Puttrich M, Weigt C, William D, Fenaux P, Schlenk RF, Thiede C, Stasik S, Mies A, Ades L, Oelschlagel U, Platzbecker U (2020). Single agent talacotuzumab demonstrates limited efficacy but considerable toxicity in elderly high-risk MDS or AML patients failing hypomethylating agents. Leukemia, 34(4), 1182-1186.
     
  30. Park S, Kelaidi C, Meunier M, Casadevall N, Gerds AT, Platzbecker U (2020). Correction to: The prognostic value of serum erythropoietin in patients with lower-risk myelodysplastic syndromes: a review of the literature and expert opinion. Ann Hematol, 99(1), 21-.
     
  31. Kayser S, Hills RK, Luskin MR, Brunner AM, Terre C, Westermann J, Menghrajani K, Shaw C, Baer MR, Elliott MA, Perl AE, Racil Z, Mayer J, Zak P, Szotkowski T, de Botton S, Grimwade D, Mayer K, Walter RB, Kramer A, Burnett AK, Ho AD, Platzbecker U, Thiede C, Ehninger G, Stone RM, Rollig C, Tallman MS, Estey EH, Muller-Tidow C, Russell NH, Schlenk RF, Levis MJ (2020). Allogeneic hematopoietic cell transplantation improves outcome of adults with t(6;9) acute myeloid leukemia: results from an international collaborative study. Haematologica, 105(1), 161-169.
     
  32. Franke GN, Maier J, Wildenberger K, Cross M, Giles FJ, Müller MC, Hochhaus A, Niederwieser D, Lange T (2020). Comparison of Real-Time Quantitative PCR and Digital Droplet PCR for BCR-ABL1 Monitoring in Patients with Chronic Myeloid Leukemia. J Mol Diagn, 22(1), 81-89.
     
  33. Kayser S, Rahmé R, Martínez-Cuadrón D, Ghiaur G, Thomas X, Sobas M, Guerci-Bresler A, Garrido A, Pigneux A, Gil C, Raffoux E, Tormo M, Vey N, de la Serna J, Salamero O, Lengfelder E, Levis MJ, Fenaux P, Sanz MA, Platzbecker U, Schlenk RF, Adès L, Montesinos P (2020). Outcome of older (?70 years) APL patients frontline treated with or without arsenic trioxide-an International Collaborative Study. Leukemia, 34(9), 2333-2341.
     
  34. Winter S, Shoaie S, Kordasti S, Platzbecker U (2020). Integrating the "Immunome" in the Stratification of Myelodysplastic Syndromes and Future Clinical Trial Design. J Clin Oncol, 38(15), 1723-1735.
     
  35. Kubasch AS, Kisro J, Heßling J, Schulz H, Hurtz HJ, Klausmann M, Ehrnsperger A, Willy C, Platzbecker U (2020). Disease management of patients with immune thrombocytopenia-results of a representative retrospective survey in Germany. Ann Hematol, 99(9), 2085-2093.
     
  36. Jentzsch M, Schwind S, Vucinic V, Wendt S, Stingu CS, Niederwieser D, Weidhase L (2020). [Meningococcal sepsis without cerebrospinal fluid abnormalities under treatment with eculizumab]. Med Klin Intensivmed Notfmed, 115(4), 340-342.
     
  37. Platzbecker U (2020). Pitfalls in Assessing Response to Treatment in MDS. Clin Lymphoma Myeloma Leuk, 20 Suppl 1(), S20-S21.
     
  38. Vinchi F, Hell S, Platzbecker U (2020). Controversies on the Consequences of Iron Overload and Chelation in MDS. Hemasphere, 4(3), e357.
     
  39. Franke GN, Kubasch AS, Cross M, Vucinic V, Platzbecker U (2020). Iron overload and its impact on outcome of patients with hematological diseases. Mol Aspects Med, 75(), 100868.
     
  40. Kubasch AS, Platzbecker U (2020). Patient stratification in myelodysplastic syndromes: how a puzzle may become a map. Hematology Am Soc Hematol Educ Program, 2020(1), 418-425.
     
  41. Franke GN, Kubasch AS, Platzbecker U (2020). Young Enough to Undergo Allogeneic Transplantation for Myelodysplastic Syndromes?: Considering the Results of the Medicare Coverage With Evidence Development Study. JAMA Oncol, 6(4), 493-494.
     
  42. Smith CC, Levis MJ, Frankfurt O, Pagel JM, Roboz GJ, Stone RM, Wang ES, Severson PL, West BL, Le MH, Kayser S, Lam B, Hsu HH, Zhang C, Bollag G, Perl AE (2020). A phase 1/2 study of the oral FLT3 inhibitor pexidartinib in relapsed/refractory FLT3-ITD-mutant acute myeloid leukemia. Blood Adv, 4(8), 1711-1721.
     
  43. Platzbecker U (2020). New Approaches for Anemia in MDS. Clin Lymphoma Myeloma Leuk, 20 Suppl 1(), 59-60.
     
  44. Platzbecker U, Kordasti S (2020). Natural born survivors: the inglorious TP53. Blood, 136(24), 2727-2728.
     
  45. Franke GN, Lückemeier P, Platzbecker U (2020). Allogeneic Stem-Cell Transplantation in Patients With Myelodysplastic Syndromes and Prevention of Relapse. Clin Lymphoma Myeloma Leuk, (), 52-55.
     
  46. Kubasch AS, Platzbecker U (2020). Patient stratification in myelodysplastic syndromes: how a puzzle may become a map. Hematology Am Soc Hematol Educ Program, 2020(1), 418-425.
     
  47. Kubasch AS, Kisro J, Heßling J, Schulz H, Hurtz HJ, Klausmann M, Ehrnsperger A, Willy C, Platzbecker U (2020). Disease management of patients with immune thrombocytopenia-results of a representative retrospective survey in Germany. Ann Hematol, 99(9), 2085-2093.
     
  48. Jentzsch M, Bill M, Grimm J, Brauer D, Backhaus D, Goldmann K, Schulz J, Niederwieser D, Platzbecker U, Schwind S (2020). Allogeneic stem cell transplantation mitigates the adverse prognostic impact of high diagnostic BAALC and MN1 expression in AML. Ann Hematol, 99(10), 2417-2427.
     
  49. Jentzsch M, Grimm J, Bill M, Brauer D, Backhaus D, Goldmann K, Schulz J, Niederwieser D, Platzbecker U, Schwind S (2020). ELN risk stratification and outcomes in secondary and therapy-related AML patients consolidated with allogeneic stem cell transplantation. Bone Marrow Transplant, (), 20-29.
     
  50. Kubasch AS, Schulze F, Giagounidis A, Götze KS, Krönke J, Sockel K, Middeke JM, Chermat F, Gloaguen S, Puttrich M, Weigt C, William D, Fenaux P, Schlenk RF, Thiede C, Stasik S, Mies A, Adès L, Oelschlägel U, Platzbecker U (2020). Single agent talacotuzumab demonstrates limited efficacy but considerable toxicity in elderly high-risk MDS or AML patients failing hypomethylating agents. Leukemia, 34(4), 1182-1186.
     
  51. Jentzsch M, Bill M, Grimm J, Schulz J, Schuhmann L, Brauer D, Goldmann K, Wilke F, Franke GN, Behre G, Pönisch W, Vucinic V, Niederwieser D, Platzbecker U, Schwind S (2020). High expression of the stem cell marker <i>GPR56</i> at diagnosis identifies acute myeloid leukemia patients at higher relapse risk after allogeneic stem cell transplantation in context with the CD34+/CD38- population. Haematologica, 105(10), 507.
     
  52. Kubasch AS, Franke GN, Aldaoud A, Weibl K, Jentzsch M, Sabri O, Horny HP, Fend F, Behre G, Platzbecker U, Vucinic V (2020). Allogeneic Hematopoietic Stem Cell Transplantation in a Rare Case of Tonsillar Mast Cell Sarcoma. Front Oncol, 10(), 219.
     
  53. Vucinic V, Jentzsch M, Schwind S, Bach E, Leiblein S, Remane Y, Rieprecht S, Otto S, Kubasch AS, Behre G, Cross M, Platzbecker U, Franke GN (2020). Case Report: Allogeneic Stem Cell Transplantation Following Induction With CPX-351 in Patients With Acute Myeloid Leukemia Is Feasible. Front Oncol, 10(), 1746.
     
  54. Schorling RM, Pfrepper C, Golombek T, Cella CA, Muñoz-Unceta N, Siegemund R, Engel C, Petros S, Lordick F, Knödler M (2020). Evaluation of Biomarkers for the Prediction of Venous Thromboembolism in Ambulatory Cancer Patients. Oncol Res Treat, 43(9), 414-427.
     
  55. Jentzsch M, Schwind S, Vucinic V, Wendt S, Stingu CS, Niederwieser D, Weidhase L (2020). [Meningococcal sepsis without cerebrospinal fluid abnormalities under treatment with eculizumab]. Med Klin Intensivmed Notfmed, 115(4), 340-342.
     
  56. Jentzsch M, Schwind S, Vucinic V, Wendt S, Stingu CS, Niederwieser D, Weidhase L (2020). [Meningococcal sepsis without cerebrospinal fluid abnormalities under treatment with eculizumab]. Med Klin Intensivmed Notfmed, 115(4), 340-342.
     
  57. Grimm J, Jentzsch M, Bill M, Goldmann K, Schulz J, Niederwieser D, Platzbecker U, Schwind S (2020). Prognostic impact of the ELN2017 risk classification in patients with AML receiving allogeneic transplantation. Blood Adv, 4(16), 3864-3874.
     
  58. Fenaux P, Platzbecker U, Mufti GJ, Garcia-Manero G, Buckstein R, Santini V, Díez-Campelo M, Finelli C, Cazzola M, Ilhan O, Sekeres MA, Falantes JF, Arrizabalaga B, Salvi F, Giai V, Vyas P, Bowen D, Selleslag D, DeZern AE, Jurcic JG, Germing U, Götze KS, Quesnel B, Beyne-Rauzy O, Cluzeau T, Voso MT, Mazure D, Vellenga E, Greenberg PL, Hellström-Lindberg E, Zeidan AM, Adès L, Verma A, Savona MR, Laadem A, Benzohra A, Zhang J, Rampersad A, Dunshee DR, Linde PG, Sherman ML, Komrokji RS, List AF (2020). Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes. N Engl J Med, 382(2), 140-151.
     
  59. Fenaux P, Platzbecker U, Mufti GJ, Garcia-Manero G, Buckstein R, Santini V, Diez-Campelo M, Finelli C, Cazzola M, Ilhan O, Sekeres MA, Falantes JF, Arrizabalaga B, Salvi F, Giai V, Vyas P, Bowen D, Selleslag D, DeZern AE, Jurcic JG, Germing U, Gotze KS, Quesnel B, Beyne-Rauzy O, Cluzeau T, Voso MT, Mazure D, Vellenga E, Greenberg PL, Hellstrom-Lindberg E, Zeidan AM, Ades L, Verma A, Savona MR, Laadem A, Benzohra A, Zhang J, Rampersad A, Dunshee DR, Linde PG, Sherman ML, Komrokji RS, List AF (2020). Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes. N Engl J Med, 382(2), 140-151.
     
  60. Smith CC, Levis MJ, Frankfurt O, Pagel JM, Roboz GJ, Stone RM, Wang ES, Severson PL, West BL, Le MH, Kayser S, Lam B, Hsu HH, Zhang C, Bollag G, Perl AE (2020). A phase 1/2 study of the oral FLT3 inhibitor pexidartinib in relapsed/refractory FLT3-ITD-mutant acute myeloid leukemia. Blood Adv, 4(8), 1711-1721.
     
  61. Stasik S, Middeke JM, Kramer M, Röllig C, Krämer A, Scholl S, Hochhaus A, Crysandt M, Brümmendorf TH, Naumann R, Steffen B, Kunzmann V, Einsele H, Schaich M, Burchert A, Neubauer A, Schäfer-Eckart K, Schliemann C, Krause S, Herbst R, Hänel M, Frickhofen N, Noppeney R, Kaiser U, Baldus CD, Kaufmann M, Rácil Z, Platzbecker U, Berdel WE, Mayer J, Serve H, Müller-Tidow C, Ehninger G, Bornhäuser M, Schetelig J, Thiede C (2020). EZH2 mutations and impact on clinical outcome: an analysis in 1,604 patients with newly diagnosed acute myeloid leukemia. Haematologica, 105(5), 228-231.
     
  62. Zader J, Vucinic V, Simon JC, Treudler R (2020). Recalcitrant pemphigus successfully treated with lenalidomide. Eur J Dermatol, 30(2), 178-179.
     
  63. Saussele S, Haverkamp W, Lang F, Koschmieder S, Kiani A, Jentsch-Ullrich K, Stegelmann F, Pfeifer H, La Rosée P, Goekbuget N, Rieger C, Waller CF, Franke GN, le Coutre P, Kirchmair R, Junghanss C (2020). Ponatinib in the Treatment of Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Leukemia: Recommendations of a German Expert Consensus Panel with Focus on Cardiovascular Management. Acta Haematol, 143(3), 217-231.
     
  64. Meyer HJ, Pönisch W, Monecke A, Gundermann P, Surov A (2020). Can Diagnostic Low-dose Whole-body CT Reflect Bone Marrow Findings in Systemic Mastocytosis? Anticancer Res, 40(2), 1015-1022.
     
  65. Cicconi L, Platzbecker U, Avvisati G, Paoloni F, Thiede C, Vignetti M, Fazi P, Ferrara F, Divona M, Albano F, Efficace F, Sborgia M, Di Bona E, Breccia M, Borlenghi E, Cairoli R, Rambaldi A, Melillo L, La Nasa G, Fiedler W, Brossart P, Hertenstein B, Salih HR, Annibali O, Wattad M, Lubbert M, Brandts CH, Hanel M, Rollig C, Schmitz N, Link H, Frairia C, Fozza C, Maria D'Arco A, Di Renzo N, Cortelezzi A, Fabbiano F, Dohner K, Ganser A, Dohner H, Amadori S, Mandelli F, Voso MT, Ehninger G, Schlenk (2020). Long-term results of all-trans retinoic acid and arsenic trioxide in non-high-risk acute promyelocytic leukemia: update of the APL0406 Italian-German randomized trial. Leukemia, 34(3), 914-918.
     
  66. Martinez-Høyer S, Deng Y, Parker J, Jiang J, Mo A, Docking TR, Gharaee N, Li J, Umlandt P, Fuller M, Jädersten M, Kulasekararaj A, Malcovati L, List AF, Hellström-Lindberg E, Platzbecker U, Karsan A (2020). Loss of lenalidomide-induced megakaryocytic differentiation leads to therapy resistance in del(5q) myelodysplastic syndrome. Nat Cell Biol, 22(5), 526-533.
     
  67. Spyridonidis A, Labopin M, Savani BN, Niittyvuopio R, Blaise D, Craddock C, Socié G, Platzbecker U, Beelen D, Milpied N, Cornelissen JJ, Ganser A, Huynh A, Griskevicius L, Giebel S, Aljurf M, Brissot E, Malard F, Esteve J, Peric Z, Baron F, Ruggeri A, Schmid C, Gilleece M, Gorin NC, Lanza F, Shouval R, Versluis J, Bug G, Fløisand Y, Ciceri F, Sanz J, Bazarbachi A, Nagler A, Mohty M (2020). Redefining and measuring transplant conditioning intensity in current era: a study in acute myeloid leukemia patients. Bone Marrow Transplant, 55(6), 1114-1125.
     
  68. Jentzsch M, Bill M, Grimm J, Brauer D, Backhaus D, Goldmann K, Schulz J, Niederwieser D, Platzbecker U, Schwind S (2020). Allogeneic stem cell transplantation mitigates the adverse prognostic impact of high diagnostic BAALC and MN1 expression in AML. Ann Hematol, 99(10), 2417-2427.
     
  69. Heinicke T, Labopin M, Polge E, Niederwieser D, Platzbecker U, Sengelov H, Choi G, Cornelissen J, Blaise D, Kuball J, van Gorkom G, Schaap N, Potter V, Paul F, Savani BN, Nagler A, Mohty M (2020). Fludarabine/busulfan versus fludarabine/total-body-irradiation (2?Gy) as conditioning prior to allogeneic stem cell transplantation in patients (?60 years) with acute myelogenous leukemia: a study of the acute leukemia working party of the EBMT. Bone Marrow Transplant, 55(4), 729-739.
     
  70. Fenaux P, Platzbecker U, Ades L (2020). How we manage adults with myelodysplastic syndrome. Br J Haematol, 189(6), 1016-1027.
     
  71. Röllig C, Kramer M, Schliemann C, Mikesch JH, Steffen B, Krämer A, Noppeney R, Schäfer-Eckart K, Krause SW, Hänel M, Herbst R, Kunzmann V, Einsele H, Jost E, Brümmendorf TH, Scholl S, Hochhaus A, Neubauer A, Sohlbach K, Fransecky L, Kaufmann M, Niemann D, Schaich M, Frickhofen N, Kiani A, Heits F, Krümpelmann U, Kaiser U, Kullmer J, Wass M, Stölzel F, von Bonin M, Middeke JM, Thiede C, Schetelig J, Berdel WE, Ehninger G, Baldus CD, Müller-Tidow C, Platzbecker U, Serve H, Bornhäuser M (2020). Does time from diagnosis to treatment affect the prognosis of patients with newly diagnosed acute myeloid leukemia? Blood, 136(7), 823-830.
     
  72. Stojkov K, Silzle T, Stussi G, Schwappach D, Bernhard J, Bowen D, ?ermák J, Dinmohamed AG, Eeltink C, Eggmann S, Fenaux P, Germing U, Haschke M, Hellstrom-Lindberg E, Heger M, van de Loosdrecht AA, Passweg J, Pfeilstöcker M, Platzbecker U, Malcovati L, de Almeida AM, Mittelman M, Morgenthaler C, Steensma DP, Santini V, Stauder R, Symeonidis A, Schär S, Maddox C, de Witte T, Bohlius J, Bonadies N (2020). Guideline-based indicators for adult patients with myelodysplastic syndromes. Blood Adv, 4(16), 4029-4044.
     
  73. Santini V, Fenaux P, Giagounidis A, Platzbecker U, List AF, Haferlach T, Zhong J, Wu C, Mavrommatis K, Beach CL, MacBeth KJ, Almeida A (2020). Impact of somatic mutations on response to lenalidomide in lower-risk non-del(5q) myelodysplastic syndromes patients. Leukemia, (), 75-61.
     
  74. Gagelmann N, Bogdanov R, Stölzel F, Rautenberg C, Panagiota V, Becker H, Radujkovic A, Luft T, Christopeit M, Finke J, Platzbecker U, Ditschkowski M, Schroeder T, Koldehoff M, Heuser M, Kobbe G, Beelen DW, Germing U, Kröger N (2020). Long-Term Survival Benefit after Allogeneic Hematopoietic Cell Transplantation for Chronic Myelomonocytic Leukemia. Biol Blood Marrow Transplant, (), 83-87.
     
  75. Grimm J, Jentzsch M, Bill M, Goldmann K, Schulz J, Niederwieser D, Platzbecker U, Schwind S (2020). Prognostic impact of the ELN2017 risk classification in patients with AML receiving allogeneic transplantation. Blood Adv, 4(16), 3864-3874.
     
  76. Weidner H, Baschant U, Lademann F, Ledesma Colunga MG, Balaian E, Hofbauer C, Misof BM, Roschger P, Blouin S, Richards WG, Platzbecker U, Hofbauer LC, Rauner M (2020). Increased FGF-23 levels are linked to ineffective erythropoiesis and impaired bone mineralization in myelodysplastic syndromes. JCI Insight, 5(15), 15-18.
     
  77. Jann JC, Streuer A, Hecht A, Nolte F, Nowak V, Danner J, Obländer J, Palme I, Lengfelder E, Platzbecker U, Hofmann WK, Flach J, Nowak D (2020). RNA-sequencing of acute promyelocytic leukemia primary blasts reveals novel molecular biomarkers of early death events. Leuk Lymphoma, 61(13), 3066-3077.
     
  78. Caocci G, Vignetti M, Patriarca A, Breccia M, Platzbecker U, Palumbo GA, Stauder R, Cottone F, Petranovic D, Voso MT, Tafuri A, Invernizzi R, Caers J, Luppi M, La Nasa G, Niscola P, Efficace F (2020). High serum ferritin levels in newly diagnosed patients with myelodysplastic syndromes are associated with greater symptom severity. Int J Hematol, 112(2), 141-146.
     
  79. Becker H, Pfeifer D, Ihorst G, Pantic M, Wehrle J, Rüter BH, Bullinger L, Hackanson B, Germing U, Kuendgen A, Platzbecker U, Döhner K, Ganser A, Hagemeijer A, Wijermans PW, Döhner H, Duyster J, Lübbert M (2020). Monosomal karyotype and chromosome 17p loss or TP53 mutations in decitabine-treated patients with acute myeloid leukemia. Ann Hematol, 99(7), 1551-1560.
     
  80. Spyridonidis A, Labopin M, Savani BN, Niittyvuopio R, Blaise D, Craddock C, Socié G, Platzbecker U, Beelen D, Milpied N, Cornelissen JJ, Ganser A, Huynh A, Griskevicius L, Giebel S, Aljurf M, Brissot E, Malard F, Esteve J, Peric Z, Baron F, Ruggeri A, Schmid C, Gilleece M, Gorin NC, Lanza F, Shouval R, Versluis J, Bug G, Fløisand Y, Ciceri F, Sanz J, Bazarbachi A, Nagler A, Mohty M (2020). Correction: Redefining and measuring transplant conditioning intensity in current era: a study in acute myeloid leukemia patients. Bone Marrow Transplant, 55(6), 1213.
     
  81. Heinicke T, Labopin M, Polge E, Stelljes M, Ganser A, Tischer J, Brecht A, Kröger N, Beelen DW, Scheid C, Bethge W, Dreger P, Bunjes D, Wagner E, Platzbecker U, Savani BN, Nagler A, Mohty M (2020). Evaluation of six different types of sequential conditioning regimens for allogeneic stem cell transplantation in relapsed/refractory acute myelogenous leukemia - a study of the Acute Leukemia Working Party of the EBMT. Leuk Lymphoma, (), 1-11.
     
  82. Efficace F, Cottone F, Oswald LB, Cella D, Patriarca A, Niscola P, Breccia M, Platzbecker U, Palumbo GA, Caocci G, Stauder R, Ricco A, Petranovic D, Caers J, Luppi M, Fianchi L, Frairia C, Capodanno I, Follini E, Sarlo C, Fazi P, Vignetti M (2020). The IPSS-R more accurately captures fatigue severity of newly diagnosed patients with myelodysplastic syndromes compared with the IPSS index. Leukemia, 34(9), 2451-2459.
     
  83. Wass M, Göllner S, Besenbeck B, Schlenk RF, Mundmann P, Göthert JR, Noppeney R, Schliemann C, Mikesch JH, Lenz G, Dugas M, Wermke M, Röllig C, Bornhäuser M, Serve H, Platzbecker U, Foerster KI, Burhenne J, Haefeli WE, Müller LP, Binder M, Pabst C, Müller-Tidow C (2020). A proof of concept phase I/II pilot trial of LSD1 inhibition by tranylcypromine combined with ATRA in refractory/relapsed AML patients not eligible for intensive therapy. Leukemia, (), 1-11.
     
  84. Bodor DL, Pönisch W, Endres RG, Paluch EK (2020). Of Cell Shapes and Motion: The Physical Basis of Animal Cell Migration. Dev Cell, 52(5), 550-562.
     
  85. Schuff-Werner P, Pönisch W, Berg T, Kaiser T (2020). Transient Howell-Jolly-body-like cytoplasmic inclusions in neutrophils after severe intoxication with alpha-lipoic acid. Scand J Clin Lab Invest, (), 1-4.
     
  86. Meyer HJ, Pönisch W, Monecke A, Gundermann P, Surov A (2020). Bone mineral density in patients with systemic mastocytosis: correlations with clinical and histopathological features. Clin Exp Rheumatol, (), 20-25.
     
  87. Dold SM, Möller MD, Ihorst G, Langer C, Pönisch W, Mügge LO, Knop S, Jung J, Greil C, Wäsch R, Engelhardt M (2020). Validation of the revised myeloma comorbidity index and other comorbidity scores in a multicenter German study group multiple myeloma trial. Haematologica, (), 20-30.
     
  88. Ludwig H, Pönisch W, Knop S, Egle A, Hinke A, Schreder M, Lechner D, Hajek R, Gunsilius E, Petzer A, Weisel K, Niederwieser D, Einsele H, Willenbacher W, Rumpold H, Pour L, Jelinek T, Krenosz KJ, Meckl A, Nolte S, Melchardt T, Greil R, Zojer N (2020). Quality of life in patients with relapsed/refractory multiple myeloma during ixazomib-thalidomide-dexamethasone induction and ixazomib maintenance therapy and comparison to the general population. Leuk Lymphoma, 61(2), 377-386.
     
  89. Heuser M, Palmisiano N, Mantzaris I, Mims A, DiNardo C, Silverman LR, Wang ES, Fiedler W, Baldus C, Schwind S, Pardee T, Perl AE, Cai C, Kaulfuss S, Lagkadinou E, Rentzsch C, Wagner M, Wilkinson G, Wu B, Jeffers M, Genvresse I, Krämer A (2020). Safety and efficacy of BAY1436032 in IDH1-mutant AML: phase I study results. Leukemia, 34(11), 2903-2913.
     
  90. Fuchs D, Kilbertus A, Kofler K, von Bubnoff N, Shoumariyeh K, Zanotti R, Bonadonna P, Scaffidi L, Doubek M, Elberink HO, Span LFR, Hermine O, Elena C, Benvenuti P, Yavuz AS, Brockow K, Zink A, Aberer E, Gorska A, Romantowski J, Hadzijusufovic E, Fortina AB, Caroppo F, Perkins C, Illerhaus A, Panse J, Vucinic V, Jawhar M, Sabato V, Triggiani M, Parente R, Bergström A, Breynaert C, Gotlib J, Reiter A, Hartmann K, Niedoszytko M, Arock M, Kluin-Nelemans HC, Sperr WR, Greul R, Valent P (2020). Scoring the risk of having systemic mastocytosis in adult patients with mastocytosis in the skin. J Allergy Clin Immunol Pract, (), 13-19.
     
  91. Zader J, Vucinic V, Simon JC, Treudler R (2020). Recalcitrant pemphigus successfully treated with lenalidomide. Eur J Dermatol, 30(2), 178-179.
     
  92. Schultze-Florey CR, Peczynski C, de Marino I, Polge E, Socié G, Blaise D, Beelen D, Franke GN, Kröger N, Stelljes M, Afanasyev B, Potter V, Gerbitz A, Schetelig J, Peric Z, Schoemans H, Koenecke C, Basak GW (2020). Frequency of lethal central nervous system neurotoxicity in patients undergoing allogeneic stem cell transplantation: a retrospective registry analysis. Bone Marrow Transplant, 55(8), 1642-1646.
     
  93. Cooper JP, Storer BE, Granot N, Gyurkocza B, Sorror ML, Chauncey TR, Shizuru J, Franke GN, Maris MB, Boyer M, Bruno B, Sahebi F, Langston AA, Hari P, Agura ED, Petersen SL, Maziarz RT, Bethge W, Asch J, Gutman JA, Olesen G, Yeager AM, Hübel K, Hogan WJ, Maloney DG, Mielcarek M, Martin PJ, Flowers MED, Georges GE, Woolfrey AE, Deeg HJ, Scott BL, McDonald GB, Storb R, Sandmaier BM (2020). Allogeneic hematopoietic cell transplantation with non-myeloablative conditioning for patients with hematologic malignancies: Improved outcomes over two decades. Haematologica, (), 20-25.
     
  94. Pouyiourou M, Meyer A, Stroux A, Viardot A, La Rosée P, Maschmeyer G, Kämpfe D, Kahl C, Vucinic V, Monecke A, Hirt C, Weber T, Meissner J, Witzens-Harig M, Böttcher S, Schmalenberg H, Marks R, Prange-Krex G, Kroschinsky F, Hauf E, Keller U, Koch K, Klapper W, Herold M, Scholz CW (2020). First-line treatment with R-CHOP or rituximab-bendamustine in patients with follicular lymphoma grade 3A-results of a retrospective analysis. Ann Hematol, 99(12), 2821-2829.
     
  95. Mytilineos D, Tsamadou C, Neuchel C, Platzbecker U, Bunjes D, Schub N, Wagner-Drouet E, Wulf G, Kröger N, Murawski N, Einsele H, Schaefer-Eckart K, Freitag S, Casper J, Kaufmann M, Dürholt M, Hertenstein B, Klein S, Ringhoffer M, Mueller CR, Frank S, Schrezenmeier H, Fuerst D, Mytilineos J (2020). The Human Leukocyte Antigen-DPB1 Degree of Compatibility Is Determined by Its Expression Level and Mismatch Permissiveness: A German Multicenter Analysis. Front Immunol, 11(), 149-154.
     
  96. Mytilineos D, Tsamadou C, Neuchel C, Platzbecker U, Bunjes D, Schub N, Wagner-Drouet E, Wulf G, Kröger N, Murawski N, Einsele H, Schaefer-Eckart K, Freitag S, Casper J, Kaufmann M, Dürholt M, Hertenstein B, Klein S, Ringhoffer M, Mueller CR, Frank S, Schrezenmeier H, Fuerst D, Mytilineos J (2020). The Human Leukocyte Antigen-DPB1 Degree of Compatibility Is Determined by Its Expression Level and Mismatch Permissiveness: A German Multicenter Analysis. Front Immunol, 11(), 614976.
     


  97. 2019


  98. Lordick F, Platzbecker U, Büch E, Köhl U (2019). Molekulare und zellbasierte Krebstherapie ? Quo vadis? Onkologe, 25, 61-67.
     
  99. Trautmann-Grill K, Tiebel O, Holig K, Platzbecker U (2019). [Successful treatment of acquired hemophilia A with recombinant porcine factor VIII]. Med Klin Intensivmed Notfmed, 114(8), 746-748.
     
  100. Fenaux P, Kiladjian JJ, Platzbecker U (2019). Luspatercept for the treatment of anemia in myelodysplastic syndromes and primary myelofibrosis. Blood, 133(8), 790-794.
     
  101. Platzbecker U (2019). Treatment of MDS. Blood, 133(10), 1096-1107.
     
  102. Petzer V, Wermke M, Tymoszuk P, Wolf D, Seifert M, Ovacin R, Berger S, Orth-Holler D, Loacker L, Weiss G, Haas H, Platzbecker U, Theurl I (2019). Enhanced labile plasma iron in hematopoietic stem cell transplanted patients promotes Aspergillus outgrowth. Blood Adv, 3(11), 1695-1700.
     
  103. Balaian E, Weidner H, Wobus M, Baschant U, Jacobi A, Mies A, Bornhauser M, Guck J, Hofbauer LC, Rauner M, Platzbecker U (2019). Effects of rigosertib on the osteo-hematopoietic niche in myelodysplastic syndromes. Ann Hematol, 98(9), 2063-2072.
     
  104. Kubasch AS, Platzbecker U (2019). The wolf of hypomethylating agent failure: what comes next? Haematologica, 104(8), 1505-1508.
     
  105. Kubasch AS, Platzbecker U (2019). Setting Fire to ESA and EMA Resistance: New Targeted Treatment Options in Lower Risk Myelodysplastic Syndromes. Int J Mol Sci, 20(16), 000.
     
  106. Thol F, Platzbecker U (2019). Do next-generation sequencing results drive diagnostic and therapeutic decisions in MDS? Blood Adv, 3(21), 3449-3453.
     
  107. Jentzsch M, Bill M, Grimm J, Schulz J, Beinicke S, Hantschel J, Goldmann K, Ponisch W, Franke GN, Vucinic V, Cross M, Behre G, Lange T, Niederwieser D, Schwind S (2019). Prognostic Impact of Blood MN1 Copy Numbers Before Allogeneic Stem Cell Transplantation in Patients With Acute Myeloid Leukemia. Hemasphere, 3(1), 167-.
     
  108. Jentzsch M, Dohring C, Linke R, Hille A, Grimm J, Ponisch W, Vucinic V, Franke GN, Behre G, Niederwieser D, Schwind S (2019). Comparison of non-myeloablative and reduced-intensity allogeneic stem cell transplantation in older patients with myelodysplastic syndromes. Am J Hematol, 94(12), 1344-1352.
     
  109. Jentzsch M, Geus U, Grimm J, Vucinic V, Ponisch W, Franke GN, Behre G, Niederwieser D, Schwind S (2019). Pretreatment CD34+/CD38- Cell Burden as Prognostic Factor in Myelodysplastic Syndrome Patients Receiving Allogeneic Stem Cell Transplantation. Biol Blood Marrow Transplant, 25(8), 1560-1566.
     
  110. Karlas T, Weisse T, Petroff D, Beer S, Dohring C, Gnatzy F, Niederwieser D, Behre G, Mossner J, Fischer J, Troltzsch M, Wiegand J, Keim V, Franke GN (2019). Author Correction: Predicting hepatic complications of allogeneic hematopoietic stem cell transplantation using liver stiffness measurement. Bone Marrow Transplant, 54(11), 1920-.
     
  111. Jentzsch M, Schwind S, Bach E, Stasik S, Thiede C, Platzbecker U (2019). Clinical Challenges and Consequences of Measurable Residual Disease in Non-APL Acute Myeloid Leukemia. Cancers (Basel), 11(11), 000.
     
  112. Jentzsch M, Schwind S, Bach E, Stasik S, Thiede C, Platzbecker U (2019). Clinical Challenges and Consequences of Measurable Residual Disease in Non-APL Acute Myeloid Leukemia. Cancers (Basel), 11(11), 10.
     
  113. Grimm J, Bill M, Jentzsch M, Beinicke S, Hantschel J, Goldmann K, Schulz J, Cross M, Franke GN, Behre G, Vucinic V, Ponisch W, Lange T, Niederwieser D, Schwind S (2019). Clinical impact of clonal hematopoiesis in acute myeloid leukemia patients receiving allogeneic transplantation. Bone Marrow Transplant, 54(8), 1189-1197.
     
  114. Schetelig J, de Wreede LC, van Gelder M, Koster L, Finke J, Niederwieser D, Beelen D, Mufti GJ, Platzbecker U, Ganser A, Heidenreich S, Maertens J, Socie G, Brecht A, Stelljes M, Kobbe G, Volin L, Nagler A, Vitek A, Luft T, Ljungman P, Yakoub-Agha I, Robin M, Kroger N (2019). Late treatment-related mortality versus competing causes of death after allogeneic transplantation for myelodysplastic syndromes and secondary acute myeloid leukemia. Leukemia, 33(3), 686-695.
     
  115. Ribezzo F, Snoeren IAM, Ziegler S, Stoelben J, Olofsen PA, Henic A, Ferreira MV, Chen S, Stalmann USA, Buesche G, Hoogenboezem RM, Kramann R, Platzbecker U, Raaijmakers MHGP, Ebert BL, Schneider RK (2019). Rps14, Csnk1a1 and miRNA145/miRNA146a deficiency cooperate in the clinical phenotype and activation of the innate immune system in the 5q- syndrome. Leukemia, 33(7), 1759-1772.
     
  116. Zeiser R, Beelen DW, Bethge W, Bornhauser M, Bug G, Burchert A, Christopeit M, Duyster J, Finke J, Gerbitz A, Klusmann JH, Kobbe G, Lubbert M, Muller-Tidow C, Platzbecker U, Rosler W, Sauer M, Schmid C, Schroeder T, Stelljes M, Kroger N, Muller LP (2019). Biology-Driven Approaches to Prevent and Treat Relapse of Myeloid Neoplasia after Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant, 25(4), 128-140.
     
  117. Eipel M, Bozic T, Mies A, Beier F, Jost E, Brummendorf TH, Platzbecker U, Wagner W (2019). Tracking myeloid malignancies by targeted analysis of successive DNA methylation at neighboring CG dinucleotides. Haematologica, 104(8), 349-351.
     
  118. Sanz MA, Fenaux P, Tallman MS, Estey EH, Lowenberg B, Naoe T, Lengfelder E, Dohner H, Burnett AK, Chen SJ, Mathews V, Iland H, Rego E, Kantarjian H, Ades L, Avvisati G, Montesinos P, Platzbecker U, Ravandi F, Russell NH, Lo-Coco F (2019). Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet. Blood, 133(15), 1630-1643.
     
  119. Rauner M, Baschant U, Roetto A, Pellegrino RM, Rother S, Salbach-Hirsch J, Weidner H, Hintze V, Campbell G, Petzold A, Lemaitre R, Henry I, Bellido T, Theurl I, Altamura S, Colucci S, Muckenthaler MU, Schett G, Komla Ebri D, Bassett JHD, Williams GR, Platzbecker U, Hofbauer LC (2019). Transferrin receptor 2 controls bone mass and pathological bone formation via BMP and Wnt signaling. Nat Metab, 1(1), 111-124.
     
  120. Ganster C, Muller-Thomas C, Haferlach C, Strupp C, Ogata K, Germing U, Hildebrandt B, Mallo M, Lubbert M, Muller C, Sole F, Gotze KS, Vandenberghe P, Gohring G, Steinmetz T, Kroger N, Platzbecker U, Soling U, Raynaud S, Shirneshan K, Schanz J, Haase D (2019). Comprehensive analysis of isolated der(1;7)(q10;p10) in a large international homogenous cohort of patients with myelodysplastic syndromes. Genes Chromosomes Cancer, 58(10), 689-697.
     
  121. Bondu S, Alary AS, Lefevre C, Houy A, Jung G, Lefebvre T, Rombaut D, Boussaid I, Bousta A, Guillonneau F, Perrier P, Alsafadi S, Wassef M, Margueron R, Rousseau A, Droin N, Cagnard N, Kaltenbach S, Winter S, Kubasch AS, Bouscary D, Santini V, Toma A, Hunault M, Stamatoullas A, Gyan E, Cluzeau T, Platzbecker U, Ades L, Puy H, Stern MH, Karim Z, Mayeux P, Nemeth E, Park S, Ganz T, Kautz L, Kosmider O, Fontenay M (2019). A variant erythroferrone disrupts iron homeostasis in SF3B1-mutated myelodysplastic syndrome. Sci Transl Med, 11(500), 11.
     
  122. Santini V, Valcarcel D, Platzbecker U, Komrokji RS, Cleverly AL, Lahn MM, Janssen J, Zhao Y, Chiang A, Giagounidis A, Guba SC, Gueorguieva I, Girvan AC, da Silva Ferreira M, Bhagat TD, Pradhan K, Steidl U, Sridharan A, Will B, Verma A (2019). Phase II Study of the ALK5 Inhibitor Galunisertib in Very Low-, Low-, and Intermediate-Risk Myelodysplastic Syndromes. Clin Cancer Res, 25(23), 6976-6985.
     
  123. Tunger A, Sommer U, Wehner R, Kubasch AS, Grimm MO, Bachmann MP, Platzbecker U, Bornhauser M, Baretton G, Schmitz M (2019). The Evolving Landscape of Biomarkers for Anti-PD-1 or Anti-PD-L1 Therapy. J Clin Med, 8(10), 1534.
     
  124. Haiduk J, Liebetrau M, Kunz M, Gradistanac T, Vucinic V, Simon JC, Ziemer M (2019). Nekrobiotisches Xanthogranulom mit Multiorganbefall bei assoziiertem multiplen Myelom. J Dtsch Dermatol Ges, 17, 16-19.
     
  125. de Greef GE, Braakman E, van der Holt B, Janssen JJWM, Petersen E, Vucinic V, Thuss N, Grootes M, Cornelissen JJ (2019). The feasibility and efficacy of subcutaneous plerixafor for mobilization of peripheral blood stem cells in allogeneic HLA-identical sibling donors: results of the HOVON-107 study. Transfusion, 59(1), 316-324.
     
  126. Bilich T, Nelde A, Bichmann L, Roerden M, Salih HR, Kowalewski DJ, Schuster H, Tsou CC, Marcu A, Neidert MC, Lubke M, Rieth J, Schemionek M, Brummendorf TH, Vucinic V, Niederwieser D, Bauer J, Marklin M, Peper JK, Klein R, Kohlbacher O, Kanz L, Rammensee HG, Stevanovic S, Walz JS (2019). The HLA ligandome landscape of chronic myeloid leukemia delineates novel T-cell epitopes for immunotherapy. Blood, 133(6), 550-565.
     
  127. Mobius S, Schenk T, Himsel D, Maier J, Franke GN, Saussele S, Pott C, Andrikovics H, Meggyesi N, Machova-Polakova K, Zizkova H, Jurcek T, Mesanovic S, Zadro R, Gottardi E, Haenig J, Schuld P, Cross NCP, Hochhaus A, Ernst T (2019). Results of the European survey on the assessment of deep molecular response in chronic phase CML patients during tyrosine kinase inhibitor therapy (EUREKA registry). J Cancer Res Clin Oncol, 145(6), 1645-1650.
     
  128. Schulze S, Stengel R, Jaekel N, Wang SY, Franke GN, Roskos M, Schneider M, Niederwieser D, Al-Ali HK (2019). Concomitant and noncanonical JAK2 and MPL mutations in JAK2V617F- and MPLW515?L-positive myelofibrosis. Genes Chromosomes Cancer, 58(11), 747-755.
     
  129. Walker CJ, Oakes CC, Genutis LK, Giacopelli B, Liyanarachchi S, Nicolet D, Eisfeld AK, Scholz M, Brock P, Kohlschmidt J, Mrozek K, Bill M, Carroll AJ, Kolitz JE, Powell BL, Wang ES, Niederwieser DW, Stone RM, Byrd JC, Schwind S, de la Chapelle A, Bloomfield CD (2019). Genome-wide association study identifies an acute myeloid leukemia susceptibility locus near BICRA. Leukemia, 33(3), 771-775.
     
  130. Gerhardt F, Maier M, Liebert UG, Platzbecker U, Wang SY, Papp CP, Bock CT, Berg T, van Bommel F (2019). Early Detection of Hepatitis E Virus Ribavirin Resistance Using Next-Generation Sequencing. Antimicrob Agents Chemother, 64(1), 19.
     
  131. Stosic MB, Plavsa D, Mavroeidi N, Jovanovic D, Vucinic V, Stevanovic G, Sagic L, Spahic S, Rakic U, Grgurevic A (2019). Tuberculosis outbreak among high school students in Novi Pazar, Serbia 2016: a retrospective-cohort study. J Infect Dev Ctries, 13(2), 101-110.
     
  132. Gerhardt F, Maier M, Liebert UG, Platzbecker U, Wang SY, Papp CP, Bock CT, Berg T, van Bömmel F (2019). Early Detection of Hepatitis E Virus Ribavirin Resistance Using Next-Generation Sequencing. Antimicrob Agents Chemother, 64(1), 19.
     


  133. 2018


  134. Krakowsky RHE, Wurm AA, Gerloff D, Katzerke C, Brauer-Hartmann D, Hartmann JU, Wilke F, Thiede C, Muller-Tidow C, Niederwieser D, Behre G (2018). miR-451a abrogates treatment resistance in FLT3-ITD-positive acute myeloid leukemia. Blood Cancer J, 8, 36.
     
  135. Hartmann JU, Brauer-Hartmann D, Kardosova M, Wurm AA, Wilke F, Schodel C, Gerloff D, Katzerke C, Krakowsky R, Namasu CY, Bill M, Schwind S, Muller-Tidow C, Niederwieser D, Alberich-Jorda M, Behre G (2018). MicroRNA-143 targets ERK5 in granulopoiesis and predicts outcome of patients with acute myeloid leukemia. Cell Death Dis, 9, 814.
     
  136. Grimm J, Bill M, Jentzsch M, Beinicke S, Hantschel J, Goldmann K, Schulz J, Cross M, Franke GN, Behre G, Vucinic V, Ponisch W, Lange T, Niederwieser D, Schwind S (2018). Clinical impact of clonal hematopoiesis in acute myeloid leukemia patients receiving allogeneic transplantation. Bone Marrow Transplant, 00000, 00000.
     
  137. Schmalbrock LK, Bonifacio L, Bill M, Jentzsch M, Schubert K, Grimm J, Cross M, Lange T, Vucinic V, Ponisch W, Behre G, Franke GN, Niederwieser D, Schwind S (2018). Prognostic relevance of DNMT3A R882 mutations in AML patients undergoing non-myeloablative conditioning hematopoietic stem cell transplantation. Bone Marrow Transplant, 53(5), 640-643.
     
  138. Bill M, Grimm J, Jentzsch M, Kloss L, Goldmann K, Schulz J, Beinicke S, Hantschel J, Cross M, Vucinic V, Ponisch W, Behre G, Franke GN, Lange T, Niederwieser D, Schwind S (2018). Digital droplet PCR-based absolute quantification of pre-transplant NPM1 mutation burden predicts relapse in acute myeloid leukemia patients. Ann Hematol, 97, 1757-1765.
     
  139. Maier J, Lange T, Cross M, Wildenberger K, Niederwieser D, Franke GN (2018). Optimized Digital Droplet PCR for BCR-ABL Journal of molecular diagnostics, 18, 1525-1578.
     
  140. Sockel K, Platzbecker U (2018). Current and Future Treatment Options for Myelodysplastic Syndromes: More Than Hypomethylating Agents and Lenalidomide? Drugs, 78(18), 1873-1885.
     
  141. Platzbecker U, Middeke JM, Sockel K, Herbst R, Wolf D, Baldus CD, Oelschlagel U, Mutherig A, Fransecky L, Noppeney R, Bug G, Gotze KS, Kramer A, Bochtler T, Stelljes M, Groth C, Schubert A, Mende M, Stolzel F, Borkmann C, Kubasch AS, von Bonin M, Serve H, Hanel M, Duhrsen U, Schetelig J, Rollig C, Kramer M, Ehninger G, Bornhauser M, Thiede C (2018). Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial. Lancet Oncol, 19(12), 1668-1679.
     
  142. Platzbecker U, Fenaux P, Ades L, Giagounidis A, Santini V, van de Loosdrecht AA, Bowen D, de Witte T, Garcia-Manero G, Hellstrom-Lindberg E, Germing U, Stauder R, Malcovati L, Sekeres M, Steensma DP, Gloaguen S (2018). Proposals for revised IWG 2018 hematological response criteria in patients with MDS included in clinical trials. Blood, 06, 000.
     
  143. Dickinson M, Cherif H, Fenaux P, Mittelman M, Verma A, Portella MSO, Burgess P, Ramos PM, Choi J, Platzbecker U (2018). Azacitidine with or without eltrombopag for first-line treatment of intermediate- or high-risk MDS with thrombocytopenia. Blood, 132(25), 2629-2638.
     
  144. Fenaux P, Santini V, Spiriti MAA, Giagounidis A, Schlag R, Radinoff A, Gercheva-Kyuchukova L, Anagnostopoulos A, Oliva EN, Symeonidis A, Berger MH, Gotze KS, Potamianou A, Haralampiev H, Wapenaar R, Milionis I, Platzbecker U (2018). A phase 3 randomized, placebo-controlled study assessing the efficacy and safety of epoetin-? in anemic patients with low-risk MDS. Leukemia, 32(12), 2648-2658.
     
  145. Kubasch AS, Wehner R, Bazzurri S, Tunger A, Stasik S, Garzarolli M, Meinel J, Baretton G, Meier F, Thiede C, Schmitz M, Platzbecker U (2018). Clinical, molecular, and immunological responses to pembrolizumab treatment of synchronous melanoma and acute myeloid leukemia. Blood Adv, 2(11), 1187-1190.
     
  146. Kubasch AS, Platzbecker U (2018). Beyond the Edge of Hypomethylating Agents: Novel Combination Strategies for Older Adults with Advanced MDS and AML. Cancers (Basel), 10(6), 000.
     
  147. Kayser S, Schlenk RF, Platzbecker U (2018). Management of patients with acute promyelocytic leukemia. Leukemia, 32(6), 1277-1294.
     
  148. Wermke M, Eckoldt J, Gotze KS, Klein SA, Bug G, de Wreede LC, Kramer M, Stolzel F, von Bonin M, Schetelig J, Laniado M, Plodeck V, Hofmann WK, Ehninger G, Bornhauser M, Wolf D, Theurl I, Platzbecker U (2018). Enhanced labile plasma iron and outcome in acute myeloid leukaemia and myelodysplastic syndrome after allogeneic haemopoietic cell transplantation (ALLIVE): a prospective, multicentre, observational trial. Lancet Haematol, 5(5), e201-e210.
     
  149. Balaian E, Wobus M, Weidner H, Baschant U, Stiehler M, Ehninger G, Bornhauser M, Hofbauer LC, Rauner M, Platzbecker U (2018). Erythropoietin inhibits osteoblast function in myelodysplastic syndromes via the canonical Wnt pathway. Haematologica, 103(1), 61-68.
     
  150. Pfrepper C, Peschka A, Weidhase L, Kaiser T, Petros S, Metze M (2018). Management of Dabigatran-associated bleeding in two elderly patients with acute renal failure Ann Hematol, 97, 2519-2521.
     
  151. Heidel FH, Al-Ali HK, Hirt C, Kampfe D, Jentsch-Ullrich K, Junghanss C, Nowak R, Schwarzer A, Spohn C, Vucinic V, Hochhaus A, Lange T (2018). Questions arising on phlebotomy in polycythemia vera: prophylactic measures to reduce thromboembolic events require patient-focused decisions. Leukemia, 32, 2085-2087.
     
  152. Ruhnke M, Behre G, Buchheidt D, Christopeit M, Hamprecht A, Heinz W, Heussel CP, Horger M, Kurzai O, Karthaus M, Loffler J, Maschmeyer G, Penack O, Rieger C, Rickerts V, Ritter J, Schmidt-Hieber M, Sc (2018). Diagnosis of invasive fungal diseases in haematology and oncology: 2018 update of the recommendations of the infectious diseases working party of the German society for hematology and medical oncology (AGIHO). Mycoses, 61, 796-813.
     
  153. Hilger N, Mueller C, Stahl L, Mueller AM, Zoennchen B, Dluczek S, Halbich C, Wickenhauser C, Gerloff D, Wurm AA, Behre G, Kretschmer A, Fricke S (2018). Incubation of Immune Cell Grafts With MAX.16H5 IgG1 Anti-Human CD4 Antibody Prolonged Survival After Hematopoietic Stem Cell Transplantation in a Mouse Model for Fms Like Tyrosine Kinase 3 Positive Acute Myeloid Leukemia. Front Immunol, 9, 2408.
     
  154. Schmidt V, Niederwieser D, Schenk T, Behre G, Klink A, Pfrepper C, Hinke A, Beelen DW, Junghanss C, Uharek L, Kruger WH, Hochhaus A, Sayer HG (2018). Efficacy and safety of keratinocyte growth factor (palifermin) for prevention of oral mucositis in TBI-based allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant, 53, 1188-1192.
     
  155. Polom K, Boger C, Smyth E, Marrelli D, Behrens HM, Marano L, Becker T, Lordick F, Rocken C, Roviello F (2018). Synchronous metastatic gastric cancer-molecular background and clinical implications with special attention to mismatch repair deficiency. Eur J Surg Oncol, 44, 626-631.
     
  156. Boutault R, Peterlin P, Boubaya M, Sockel K, Chevallier P, Garnier A, Guillaume T, Le Bourgeois A, Debord C, Godon C, Le Bris Y, Theisen O, Kroschinsky F, Moreau P, Bene MC, Platzbecker U, Eveillard M (2018). A novel complete blood count-based score to screen for myelodysplastic syndrome in cytopenic patients. Br J Haematol, 183(5), 736-746.
     
  157. Ball B, Komrokji RS, Ades L, Sekeres MA, DeZern AE, Pleyer L, Vey N, Almeida A, Germing U, Cluzeau T, Platzbecker U, Gore SD, Fenaux P, Prebet T (2018). Evaluation of induction chemotherapies after hypomethylating agent failure in myelodysplastic syndromes and acute myeloid leukemia. Blood Adv, 2(16), 2063-2071.
     
  158. Kaivers J, Lauseker M, Hildebrandt B, Fenaux P, Pfeilstocker M, Valent P, Platzbecker U, Latagliata R, Oliva EN, Xicoy B, Gotze K, Ganster C, Haase D, Bug G, Kundgen A, Gattermann N, Haas R, Germing U (2018). The IPSS-R has prognostic impact in untreated patients with MDS del(5q). Leuk Res, 72, 27-33.
     
  159. Stahl M, DeVeaux M, de Witte T, Neukirchen J, Sekeres MA, Brunner AM, Roboz GJ, Steensma DP, Bhatt VR, Platzbecker U, Cluzeau T, Prata PH, Itzykson R, Fenaux P, Fathi AT, Smith A, Germing U, Ritchie E (2018). The use of immunosuppressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohort. Blood Adv, 2(14), 1765-1772.
     
  160. Middeke JM, Kollinger F, Baldauf H, Stolzel F, Wermke M, von Bonin M, Sockel K, Link CS, Teipel R, Rollig C, Thiede C, Platzbecker U, Ehninger G, Bornhauser M, Schetelig J (2018). Validation of the Revised Pretransplant Assessment of Mortality Score in Patients with Acute Myelogenous Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant, 24(9), 1947-1951.
     
  161. Duchmann M, Yalniz FF, Sanna A, Sallman D, Coombs CC, Renneville A, Kosmider O, Braun T, Platzbecker U, Willems L, Ades L, Fontenay M, Rampal R, Padron E, Droin N, Preudhomme C, Santini V, Patnaik MM, (2018). Prognostic Role of Gene Mutations in Chronic Myelomonocytic Leukemia Patients Treated With Hypomethylating Agents. EBioMedicine, 31, 174-181.
     
  162. Datzmann T, Trautmann F, Tesch F, Mies A, Hofbauer LC, Platzbecker U, Schmitt J (2018). Associations of myeloid hematological diseases of the elderly with osteoporosis: A longitudinal analysis of routine health care data. Leuk Res, 69, 81-86.
     
  163. Santini V, Almeida A, Giagounidis A, Platzbecker U, Buckstein R, Beach CL, Guo S, Altincatal A, Wu C, Fenaux P (2018). The Effect of Lenalidomide on Health-Related Quality of Life in Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes: Results From the MDS-005 Study. Clin Lymphoma Myeloma Leuk, 18(2), 136-144.
     
  164. Kantarjian HM, Fenaux P, Sekeres MA, Szer J, Platzbecker U, Kuendgen A, Gaidano G, Wiktor-Jedrzejczak W, Carpenter N, Mehta B, Franklin J, Giagounidis A (2018). Long-term follow-up for up to 5 years on the risk of leukaemic progression in thrombocytopenic patients with lower-risk myelodysplastic syndromes treated with romiplostim or placebo in a randomised double-blind trial. Lancet Haematol, 5(3), 117-126.
     
  165. Stasik S, Schuster C, Ortlepp C, Platzbecker U, Bornhauser M, Schetelig J, Ehninger G, Folprecht G, Thiede C (2018). An optimized targeted Next-Generation Sequencing approach for sensitive detection of single nucleotide variants. Biomol Detect Quantif, 15, 6-12.
     
  166. Harrison CN, Vannucchi AM, Platzbecker U, Cervantes F, Gupta V, Lavie D, Passamonti F, Winton EF, Dong H, Kawashima J, Maltzman JD, Kiladjian JJ, Verstovsek S (2018). Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial. Lancet Haematol, 5(2), 73-81.
     
  167. Mittelman M, Platzbecker U, Afanasyev B, Grosicki S, Wong RSM, Anagnostopoulos A, Brenner B, Denzlinger C, Rossi G, Nagler A, Garcia-Delgado R, Portella MSO, Zhu Z, Selleslag D (2018). Eltrombopag for advanced myelodysplastic syndromes or acute myeloid leukaemia and severe thrombocytopenia (ASPIRE): a randomised, placebo-controlled, phase 2 trial. Lancet Haematol, 5(1), 34-43.
     
  168. Efficace F, Cottone F, Abel G, Niscola P, Gaidano G, Bonnetain F, Anota A, Caocci G, Cronin A, Fianchi L, Breccia M, Stauder R, Platzbecker U, Palumbo GA, Luppi M, Invernizzi R, Bergamaschi M, Borin L (2018). Patient-reported outcomes enhance the survival prediction of traditional disease risk classifications: An international study in patients with myelodysplastic syndromes. Cancer, 124(6), 1251-1259.
     
  169. Tirado-Gonzalez I, Czlonka E, Nevmerzhitskaya A, Soetopo D, Bergonzani E, Mahmoud A, Contreras A, Jeremias I, Platzbecker U, Bourquin JP, Kloz U, Van der Hoeven F, Medyouf H (2018). CRISPR/Cas9-edited NSG mice as PDX models of human leukemia to address the role of niche-derived SPARC. Leukemia, 32(4), 1049-1052.
     
  170. Schroeder T, Rautenberg C, Kruger W, Platzbecker U, Bug G, Steinmann J, Klein S, Hopfer O, Nachtkamp K, Kondakci M, Geyh S, Haas R, Germing U, Bornhauser M, Kobbe G (2018). Treatment of relapsed AML and MDS after allogeneic stem cell transplantation with decitabine and DLI-a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group. Ann Hematol, 97(2), 335-342.
     
  171. Schmidt V, Niederwieser D, Schenk T, Behre G, Klink A, Pfrepper C, Hinke A, Beelen DW, Junghanss C, Uharek L, Kruger WH, Hochhaus A, Sayer HG (2018). Efficacy and safety of keratinocyte growth factor (palifermin) for prevention of oral mucositis in TBI-based allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant, 53(9), 1188-1192.
     
  172. Haiduk J, Linde J, Vucinic V, Dumann K, Ponitzsch I, Ziemer M (2018). Disseminierte erythematöse Papeln und Nodi. J Dtsch Dermatol Ges, 16(8), 1043-1046.
     
  173. Haiduk J, Linde J, Vucinic V, Dumann K, Ponitzsch I, Ziemer M (2018). Disseminierte erythematöse Papeln und Nodi. J Dtsch Dermatol Ges, 16(8), 1043-1046.
     
  174. Platzbecker U, Fenaux P (2018). Myelodysplastic syndromes: Diagnostics - Prognosis - Therapy. In: Fenaux P, Myelodysplastic syndromes: Diagnostics - Prognosis - Therapy. (S. 000-157), Basel: Springer International Publishing.
     
  175. Platzbecker U, Ehninger G (2018). Myelodysplastische Syndrome In: Ehninger G, Petrasch S, Colloquium Onkologie 26, Update Hämatologie/Onkologie 2018 (S. 000-696), München: Lukon Verlagsgesellschaft.
     


  176. 2017


  177. Pfrepper C, Siegemund A, Hildebrandt S, Kronberg J, Scholz U, Niederwieser D (2017). Prophylactic treatment of hereditary severe factor VII deficiency in pregnancy. Blood Coagul Fibrinolysis, 28(6), 490-492.
     
  178. Wurm AA, Tenen DG, Behre G (2017). The Janus-faced Nature of miR-22 in Hematopoiesis: Is It an Oncogenic Tumor Suppressor or Rather a Tumor-Suppressive Oncogene? PLoS Genet, 13(1), e1006505.
     
  179. Jentzsch M, Bill M, Grimm J, Schulz J, Goldmann K, Beinicke S, Hantschel J, Ponisch W, Franke GN, Vucinic V, Behre G, Lange T, Niederwieser D, Schwind S (2017). High BAALC copy numbers in peripheral blood prior to allogeneic transplantation predict early relapse in acute myeloid leukemia patients. Oncotarget, 8(50), 87944-87954.
     
  180. Beck J, Schwarzer A, Glaser D, Mugge LO, Uhlig J, Heyn S, Kragl B, Mohren M, Hoffmann FA, Lange T, Schliwa T, Zehrfeld T, Becker C, Kreibich U, Winkelmann C, Edelmann T, Andrea M, Bill M, Jentzsch M, Schwind S, Niederwieser D, Ponisch W (2017). Lenalidomide in combination with bendamustine and prednisolone in relapsed/refractory multiple myeloma: results of a phase 2 clinical trial (OSHO-#077). J Cancer Res Clin Oncol, 143(12), 2545-2553.
     
  181. Wurm AA, Zjablovskaja P, Kardosova M, Gerloff D, Brauer-Hartmann D, Katzerke C, Hartmann JU, Benoukraf T, Fricke S, Hilger N, Muller AM, Bill M, Schwind S, Tenen DG, Niederwieser D, Alberich-Jorda M, Behre G (2017). Disruption of the C/EBP?-miR-182 balance impairs granulocytic differentiation. Nat Commun, 8(1), 46.
     
  182. Tessenow H, Holzvogt M, Holzvogt B, Andrea M, Heyn S, Schliwa T, Schwarz M, Zehrfeld T, Becker C, Pfrepper C, Franke GN, Krahl R, Jentzsch M, Leiblein S, Schwind S, Bill M, Vucinic V, Lange T, Niederwieser D, Ponisch W (2017). Successful treatment of patients with newly diagnosed/untreated light chain multiple myeloma with a combination of bendamustine, prednisone and bortezomib (BPV). J Cancer Res Clin Oncol, 143(10), 2049-2058.
     
  183. Bill M, Jentzsch M, Grimm J, Schubert K, Lange T, Cross M, Behre G, Vucinic V, Ponisch W, Franke GN, Niederwieser D, Schwind S (2017). Prognostic impact of the European LeukemiaNet standardized reporting system in older AML patients receiving stem cell transplantation after non-myeloablative conditioning. Bone Marrow Transplant, 52(6), 932-935.
     
  184. Jentzsch M, Bill M, Nicolet D, Leiblein S, Schubert K, Pless M, Bergmann U, Wildenberger K, Schuhmann L, Cross M, Ponisch W, Franke GN, Vucinic V, Lange T, Behre G, Mrozek K, Bloomfield CD, Niederwieser D, Schwind S (2017). Prognostic impact of the CD34+/CD38- cell burden in patients with acute myeloid leukemia receiving allogeneic stem cell transplantation. Am J Hematol, 92(4), 388-396.
     
  185. Namasu CY, Katzerke C, Brauer-Hartmann D, Wurm AA, Gerloff D, Hartmann JU, Schwind S, Muller-Tidow C, Hilger N, Fricke S, Christopeit M, Niederwieser D, Behre G (2017). ABR, a novel inducer of transcription factor C/EBPalpha, contributes to myeloid differentiation and is a favorable prognostic factor in acute myeloid leukemia. Oncotarget, 8(61), 103626-103639.
     
  186. Pönisch W, Beck J (2017). Neue Therapien beim redzidivierten Multiplem Myelom. Mitteilungsblatt der saechsischen Krebsgesellschaft, 22, 6-9.
     
  187. Ponisch W, Alten R, Baerwald C (2017). [Autoimmune reactions to immune checkpoint inhibitors]. Z Rheumatol, 76(S2), 57-62.
     
  188. Platzbecker U (2017). From occasional date to civil union in APL. Blood, 129(10), 1235-.
     
  189. Mies A, Platzbecker U (2017). Increasing the effectiveness of hematopoiesis in myelodysplastic syndromes: erythropoiesis-stimulating agents and transforming growth factor-? superfamily inhibitors. Semin Hematol, 54(3), 141-146.
     
  190. Platzbecker U, Avvisati G, Cicconi L, Thiede C, Paoloni F, Vignetti M, Ferrara F, Divona M, Albano F, Efficace F, Fazi P, Sborgia M, Di Bona E, Breccia M, Borlenghi E, Cairoli R, Rambaldi A, Melillo L, La Nasa G, Fiedler W, Brossart P, Hertenstein B, Salih HR, Wattad M, Lubbert M, Brandts CH, Hanel M, Rollig C, Schmitz N, Link H, Frairia C, Pogliani EM, Fozza C, D'Arco AM, Di Renzo N, Cortelezzi A, Fabbiano F, Dohner K, Ganser A, Dohner H, Amadori S, Mandelli F, Ehninger G, Schlenk RF, Lo-Coco F (2017). Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non-High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial. J Clin Oncol, 35(6), 605-612.
     
  191. Francke S, Mies A, Meggendorfer M, Oelschlaegel U, Balaian E, Gloaguen S, Haferlach T, Ehninger G, Bornhauser M, Platzbecker U (2017). Disease-modifying activity of ruxolitinib in a patient with JAK2-negative CMML-2. Leuk Lymphoma, 58(5), 1271-1272.
     
  192. Weidner H, Rauner M, Trautmann F, Schmitt J, Balaian E, Mies A, Helas S, Baschant U, Khandanpour C, Bornhauser M, Hofbauer LC, Platzbecker U (2017). Myelodysplastic syndromes and bone loss in mice and men. Leukemia, 31(4), 1003-1007.
     
  193. Platzbecker U, Symeonidis A, Oliva EN, Goede JS, Delforge M, Mayer J, Slama B, Badre S, Gasal E, Mehta B, Franklin J (2017). A phase 3 randomized placebo-controlled trial of darbepoetin alfa in patients with anemia and lower-risk myelodysplastic syndromes. Leukemia, 31(9), 1944-1950.
     
  194. Herold S, Sockel K, Sayehli C, Herbst R, Duhrsen U, Oelschlagel U, Bottner A, Hindahl H, Kullmer J, Helas S, Sauer M, Mohr B, Mies A, Bornhauser M, Ehninger G, Rollig C, Thiede C, Platzbecker U (2017). Evolution of NPM1-negative therapy-related myelodysplastic syndromes following curative treatment of NPM1-mutant AML. Leukemia, 31(10), 2247-2251.
     
  195. Platzbecker U, Germing U, Gotze KS, Kiewe P, Mayer K, Chromik J, Radsak M, Wolff T, Zhang X, Laadem A, Sherman ML, Attie KM, Giagounidis A (2017). Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study. Lancet Oncol, 18(10), 1338-1347.
     
  196. Hecht A, Doll S, Altmann H, Nowak D, Lengfelder E, Rollig C, Ehninger G, Spiekermann K, Hiddemann W, Weiss C, Hofmann WK, Nolte F, Platzbecker U (2017). Validation of a Molecular Risk Score for Prognosis of Patients With Acute Promyelocytic Leukemia Treated With All-trans Retinoic Acid and Chemotherapy-containing Regimens. Clin Lymphoma Myeloma Leuk, 17(12), 889-896.
     
  197. Kayser S, Krzykalla J, Elliott MA, Norsworthy K, Gonzales P, Hills RK, Baer MR, Racil Z, Mayer J, Novak J, Zak P, Szotkowski T, Grimwade D, Russell NH, Walter RB, Estey EH, Westermann J, Gorner M, Benner A, Kramer A, Smith BD, Burnett AK, Thiede C, Rollig C, Ho AD, Ehninger G, Schlenk RF, Tallman MS, Levis MJ, Platzbecker U (2017). Characteristics and outcome of patients with therapy-related acute promyelocytic leukemia front-line treated with or without arsenic trioxide. Leukemia, 31(11), 2347-2354.
     
  198. Heidenreich S, Ziagkos D, de Wreede LC, van Biezen A, Finke J, Platzbecker U, Niederwieser D, Einsele H, Bethge W, Schleuning M, Beelen DW, Tischer J, Nagler A, Glass B, Maertens J, Yanez L, Beguin Y, (2017). Allogeneic Stem Cell Transplantation for Patients with Myelodysplastic Syndrome 70 Years of Age or Older: a Retrospective Study of the MDS Subcommittee of the Chronic Malignancies Working Party (CMWP) of the EBMT. Biol Blood Marrow Transplant, 23(1), 44-52.
     
  199. Dias A, Al-Kali A, Van Dyke D, Niederwieser D, Vucinic V, Lemke J, Muller C, Schwind S, Teichmann AC, Bakken R, Burns LJ, Litzow M (2017). Inversion 3 Cytogenetic Abnormality in an Allogeneic Hematopoietic Cell Transplant Recipient Representative of a Donor-Derived Constitutional Abnormality. Biol Blood Marrow Transplant, 23(9), 1582-1587.
     
  200. Backert L, Kowalewski DJ, Walz S, Schuster H, Berlin C, Neidert MC, Schemionek M, Brummendorf TH, Vucinic V, Niederwieser D, Kanz L, Salih HR, Kohlbacher O, Weisel K, Rammensee HG, Stevanovic S, Walz (2017). A meta-analysis of HLA peptidome composition in different hematological entities: entity-specific dividing lines and pan-leukemia antigens. Oncotarget, 8(27), 43915-43924.
     
  201. Blank V, Schierle K, Hacker U, Herta T, Vucinic V, Hoffmeister A, Mossner J, Jansen-Winkeln B, Keim V, Karlas T (2017). An unusual hypoechoic solid mass in the pancreatic head. Z Gastroenterol, 55(4), 375-378.
     
  202. Herold S, Kuhn M, Bonin MV, Stange T, Platzbecker U, Radke J, Lange T, Sockel K, Gutsche K, Schetelig J, Rollig C, Schuster C, Roeder I, Dahl A, Mohr B, Serve H, Brandts C, Ehninger G, Bornhauser M, T (2017). Donor cell leukemia: evidence for multiple preleukemic clones and parallel long term clonal evolution in donor and recipient. Leukemia, 31(7), 1637-1640.
     
  203. Merz M, Kellermann L, Poenisch W, Tischler HJ, Kohnke J, Knauf W, Goldschmidt H (2017). Diagnosis and treatment of multiple myeloma in Germany: analysis of a nationwide multi-institutional survey. Ann Hematol, 96(6), 987-993.
     
  204. Heidenreich S, Ziagkos D, de Wreede LC, van Biezen A, Finke J, Platzbecker U, Niederwieser D, Einsele H, Bethge W, Schleuning M, Beelen DW, Tischer J, Nagler A, Glass B, Maertens J, Yanez L, Beguin Y, (2017). Allogeneic Stem Cell Transplantation for Patients Age ? 70 Years with Myelodysplastic Syndrome: A Retrospective Study of the MDS Subcommittee of the Chronic Malignancies Working Party of the EBMT. Biol Blood Marrow Transplant, 23(1), 44-52.
     
  205. Schlenk RF, Stegelmann F, Reiter A, Jost E, Gattermann N, Hebart H, Waller C, Hochhaus A, Platzbecker U, Schafhausen P, Blau IW, Verbeek W, Heidel FH, Werner M, Kreipe H, Teleanu V, Benner A, Dohner H (2017). Pomalidomide in myeloproliferative neoplasm-associated myelofibrosis. Leukemia, 31(4), 889-895.
     
  206. Almeida A, Fenaux P, List AF, Raza A, Platzbecker U, Santini V (2017). Recent advances in the treatment of lower-risk non-del(5q) myelodysplastic syndromes (MDS). Leuk Res, 52, 50-57.
     
  207. de Witte T, Bowen D, Robin M, Malcovati L, Niederwieser D, Yakoub-Agha I, Mufti GJ, Fenaux P, Sanz G, Martino R, Alessandrino EP, Onida F, Symeonidis A, Passweg J, Kobbe G, Ganser A, Platzbecker U, Fi (2017). Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel. Blood, 129(13), 1753-1762.
     
  208. Schanda J, Lee CW, Wohlan K, Muller-Kuller U, Kunkel H, Coco IQ, Stein S, Metz A, Koch J, Lausen J, Platzbecker U, Medyouf H, Gohlke H, Heuser M, Eder M, Grez M, Scherr M, Wichmann C (2017). Suppression of RUNX1/ETO oncogenic activity by a small molecule inhibitor of tetramerization. Haematologica, 102(5), 170-174.
     
  209. Duchmann M, Braun T, Micol JB, Platzbecker U, Park S, Pilorge S, Beyne-Rauzy O, Vey N, Sebert M, Gruson B, Dumas PY, Guieze R, Chretien ML, Laribi K, Chait Y, Legros L, Sahnes L, Hirsch P, Salanoubat (2017). Validation of response assessment according to international consortium for MDS/MPN criteria in chronic myelomonocytic leukemia treated with hypomethylating agents. Blood Cancer J, 7(5), 562.
     
  210. Braulke F, Schulz X, Germing U, Schuler E, Platzbecker U, Nolte F, Hofmann WK, Giagounidis A, Gotze K, Lubbert M, Schlenk RF, Schanz J, Bacher U, Ganser A, Busche G, Letsch A, Schafhausen P, Bug G, Br (2017). Peripheral blood cytogenetics allows treatment monitoring and early identification of treatment failure to lenalidomide in MDS patients: results of the LE-MON-5 trial. Ann Hematol, 96(6), 887-894.
     
  211. Prebet T, Cluzeau T, Park S, Sekeres MA, Germing U, Ades L, Platzbecker U, Gotze K, Vey N, Oliva E, Sugrue MM, Bally C, Kelaidi C, Al Ali N, Fenaux P, Gore SD, Komrokji R (2017). Outcome of patients treated for myelodysplastic syndromes with 5q deletion after failure of lenalidomide therapy. Oncotarget, 8(47), 81926-81935.
     
  212. Herold S, Kuhn M, Bonin MV, Stange T, Platzbecker U, Radke J, Lange T, Sockel K, Gutsche K, Schetelig J, Rollig C, Schuster C, Roeder I, Dahl A, Mohr B, Serve H, Brandts C, Ehninger G, Bornhauser M, T (2017). Donor cell leukemia: evidence for multiple preleukemic clones and parallel long term clonal evolution in donor and recipient. Leukemia, 31(7), 1637-1640.
     
  213. Kroger N, Iacobelli S, Franke GN, Platzbecker U, Uddin R, Hubel K, Scheid C, Weber T, Robin M, Stelljes M, Afanasyev B, Heim D, Deliliers GL, Onida F, Dreger P, Pini M, Guidi S, Volin L, Gunther A, Be (2017). Dose-Reduced Versus Standard Conditioning Followed by Allogeneic Stem-Cell Transplantation for Patients With Myelodysplastic Syndrome: A Prospective Randomized Phase III Study of the EBMT (RICMAC Trial). J Clin Oncol, 35(19), 2157-2164.
     
  214. Radsak M, Platzbecker U, Schmidt CS, Hofmann WK, Nolte F (2017). Infectious complications in patients with myelodysplastic syndromes: A review of the literature with emphasis on patients treated with 5-azacitidine. Eur J Haematol, 99(2), 112-118.
     
  215. Heuser M, Gabdoulline R, Loffeld P, Dobbernack V, Kreimeyer H, Pankratz M, Flintrop M, Liebich A, Klesse S, Panagiota V, Stadler M, Wichmann M, Shahswar R, Platzbecker U, Thiede C, Schroeder T, Kobbe (2017). Individual outcome prediction for myelodysplastic syndrome (MDS) and secondary acute myeloid leukemia from MDS after allogeneic hematopoietic cell transplantation. Ann Hematol, 96(8), 1361-1372.
     
  216. Jann JC, Nowak D, Nolte F, Fey S, Nowak V, Oblander J, Pressler J, Palme I, Xanthopoulos C, Fabarius A, Platzbecker U, Giagounidis A, Gotze K, Letsch A, Haase D, Schlenk R, Bug G, Lubbert M, Ganser A, (2017). Accurate quantification of chromosomal lesions via short tandem repeat analysis using minimal amounts of DNA. J Med Genet, 54(9), 640-650.
     
  217. Jawhar M, Naumann N, Schwaab J, Baurmann H, Casper J, Dang TA, Dietze L, Dohner K, Hanel A, Lathan B, Link H, Lotfi S, Maywald O, Mielke S, Muller L, Platzbecker U, Prummer O, Thomssen H, Topelt K, Pa (2017). Imatinib in myeloid/lymphoid neoplasms with eosinophilia and rearrangement of PDGFRB in chronic or blast phase. Ann Hematol, 96(9), 1463-1470.
     
  218. Buttner B, Knoth H, Kramer M, Oertel R, Seeling A, Sockel K, von Bonin M, Stolzel F, Alakel N, Platzbecker U, Rollig C, Ehninger G, Bornhauser M, Schetelig J, Middeke JM (2017). Impact of pharmacokinetics on the toxicity and efficacy of clofarabine in patients with relapsed or refractory acute myeloid leukemia. Leuk Lymphoma, 58(12), 2865-2874.
     
  219. Kayser S, Feszler M, Krzykalla J, Schick M, Kramer M, Benner A, Thol F, Platzbecker U, Muller-Tidow C, Ho AD, Ehninger G, Heuser M, Schlenk RF, Thiede C, Rollig C, Kramer A (2017). Clinical impact of KMT2C and SPRY4 expression levels in intensively treated younger adult acute myeloid leukemia patients. Eur J Haematol, 99(6), 544-552.
     
  220. Nazha A, Sekeres MA, Komrokji R, Steensma DP, Kantarjian H, Roboz G, Fenaux P, Prebet T, Azarnia N, Zbyszewski PS, Fruchtman SM, Santini V, Silverman LR, Platzbecker U, Garcia-Manero G (2017). Validation of a post-hypomethylating agent failure prognostic model in myelodysplastic syndromes patients treated in a randomized controlled phase III trial of rigosertib vs. best supportive care. Blood Cancer J, 7(12), 644-.
     
  221. Tsamadou C, Furst D, Vucinic V, Bunjes D, Neuchel C, Mytilineos D, Gramatzki M, Arnold R, Wagner EM, Einsele H, Muller C, Schrezenmeier H, Mytilineos J (2017). Human leukocyte antigen-E mismatch is associated with better hematopoietic stem cell transplantation outcome in acute leukemia patients. Haematologica, 102(11), 1947-1955.
     
  222. Pfrepper C, Siegemund A, Hildebrandt S, Kronberg J, Scholz U, Niederwieser D (2017). Prophylactic treatment of hereditary severe factor VII deficiency in pregnancy. Blood Coagul Fibrinolysis, 28(6), 490-492.
     
  223. Behrens A, Lordick F (2017). Facharztwissen Gastroenterologie. In: Layer P, Rosien U, Magenkarzinom. (S. 134-145), München: Elsevier Verlag.
     
  224. Behrens A, Lordick F (2017). Facharztwissen Gastroenterologie. In: Layer P, Rosien U, Ösophagustumoren. (S. 100-110), München: Elsevier Verlag.
     
  225. Platzbecker U (2017). Hämorrhagische Diathesen In: Herold G, Innere Medizin 2018 (S. 000-999), Kandern: Unimedica Verlag.
     
  226. Platzbecker U, Ehninger G (2017). Update Hämatologie/Onkologie 2017 In: Ehninger G, Petrasch S, In Colloquium Onkologie 24 (S. 000-696), München: Lukon Verlagsgesellschaft.
     


  227. 2016


  228. Pfrepper C, Klinik A, Behre G, Schenk T, Franke GN, Jentzsch M, Schwind S, Al-Ali HK, Hochhaus A, Niederwieser D, Sayer HG (2016). Risk factors for outcome in refractory acute myeloid leukemia patients treated with a combination of fludarabine, cytarabine, and amsacrine followed by a reduced-intensity conditioning and allogeneic stem cell transplantation. J Cancer Res Clin Oncol, 142(1), 317-324.
     
  229. Jaekel N, Lieder K, Albrecht S, Leismann O, Hubert K, Bug G, Kroger N, Platzbecker U, Stadler M, de Haas K, Altamura S, Muckenthaler MU, Niederwieser D, Al-Ali HK (2016). Efficacy and safety of deferasirox in non-thalassemic patients with elevated ferritin levels after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant, 51(1), 89-95.
     
  230. Pfrepper C, Klink A, Behre G, Schenk T, Franke GN, Jentzsch M, Schwind S, Al-Ali HK, Hochhaus A, Niederwieser D, Sayer HG (2016). Risk factors for outcome in refractory acute myeloid leukemia patients treated with a combination of fludarabine, cytarabine, and amsacrine followed by a reduced-intensity conditioning and allogeneic stem cell transplantation. J Cancer Res Clin Oncol, 142(1), 317-324.
     
  231. Mies A, Hermine O, Platzbecker U (2016). Activin Receptor II Ligand Traps and Their Therapeutic Potential in Myelodysplastic Syndromes with Ring Sideroblasts. Curr Hematol Malig Rep, 11(6), 416-424.
     
  232. Platzbecker U, Fenaux P (2016). Recent frustration and innovation in myelodysplastic syndrome. Haematologica, 101(8), 891-893.
     
  233. Wermke M, Schuster C, Nolte F, Al-Ali HK, Kiewe P, Schonefeldt C, Jakob C, von Bonin M, Hentschel L, Klut IM, Ehninger G, Bornhauser M, Baretton G, Germing U, Herbst R, Haase D, Hofmann WK, Platzbecker U (2016). Mammalian-target of rapamycin inhibition with temsirolimus in myelodysplastic syndromes (MDS) patients is associated with considerable toxicity: results of the temsirolimus pilot trial by the German MDS Study Group (D-MDS). Br J Haematol, 175(5), 917-924.
     
  234. Schuler MK, Hentschel L, Gobel J, Balaian E, Hornemann B, Hoffmann J, Kramer M, Kasten P, Bornhauser M, Ehninger G, Platzbecker U (2016). Effects of a home-based exercise program on physical capacity and fatigue in patients with low to intermediate risk myelodysplastic syndrome-a pilot study. Leuk Res, 47, 128-135.
     
  235. Mies A, Bulycheva E, Rogulj IM, Hofbauer LC, Platzbecker U (2016). Alterations within the Osteo-Hematopoietic Niche in MDS and their Therapeutic Implications. Curr Pharm Des, 22(16), 2323-2332.
     
  236. Oelschlaegel U, Alexander Rohnert M, Mohr B, Sockel K, Herold S, Ehninger G, Bornhauser M, Thiede C, Platzbecker U (2016). Clonal architecture of del(5q) myelodysplastic syndromes: aberrant CD5 or CD7 expression within the myeloid progenitor compartment defines a subset with high clonal burden. Leukemia, 30(2), 517-520.
     
  237. Petros S (2016). [Thromboprophylaxis in the critically ill : Low molecular weight heparin versus unfractionated heparin]. Med Klin Intensivmed Notfmed, 111(1), 55-56.
     
  238. Petros S (2016). [Therapy with blood products]. Med Klin Intensivmed Notfmed, 111(3), 241-252.
     
  239. Niederwieser C, Starke S, Fischer L, Krahl R, Beck J, Gruhn B, Ebell W, Korholz D, Wossmann W, Bader P, Lang P, Al-Ali HK, Cross M, Eisfeld AK, Heyn S, Vucinic V, Franke GN, Lange T, Ponisch W, Behre (2016). Favorable outcome in children and adolescents with a high proportion of advanced phase disease using single/multiple autologous or matched/mismatched allogeneic stem cell transplantations. Ann Hematol, 95(3), 473-481.
     
  240. Balaian E, Schuster C, Schonefeldt C, Germing U, Haase D, Tuve S, Ordemann R, Ehninger G, Bornhauser M, Oelschlaegel U, Mohr B, von Bonin M, Platzbecker U, Wermke M (2016). Selective expansion of regulatory T cells during lenalidomide treatment of myelodysplastic syndrome with isolated deletion 5q. Ann Hematol, 95(11), 1805-1810.
     
  241. Lubbert M, Suciu S, Hagemeijer A, Ruter B, Platzbecker U, Giagounidis A, Selleslag D, Labar B, Germing U, Salih HR, Muus P, Pfluger KH, Schaefer HE, Bogatyreva L, Aul C, de Witte T, Ganser A, Becker H (2016). Decitabine improves progression-free survival in older high-risk MDS patients with multiple autosomal monosomies: results of a subgroup analysis of the randomized phase III study 06011 of the EORTC Leukemia Cooperative Group and German MDS Study Group. Ann Hematol, 95(2), 191-199.
     
  242. von Dalowski F, Kramer M, Wermke M, Wehner R, Rollig C, Alakel N, Stolzel F, Parmentier S, Sockel K, Krech M, Schmitz M, Platzbecker U, Schetelig J, Bornhauser M, von Bonin M (2016). Mesenchymal Stromal Cells for Treatment of Acute Steroid-Refractory Graft Versus Host Disease: Clinical Responses and Long-Term Outcome. Stem Cells, 34(2), 357-366.
     
  243. Schneider RK, Schenone M, Ferreira MV, Kramann R, Joyce CE, Hartigan C, Beier F, Brummendorf TH, Germing U, Platzbecker U, Busche G, Knuchel R, Chen MC, Waters CS, Chen E, Chu LP, Novina CD, Lindsley (2016). Rps14 haploinsufficiency causes a block in erythroid differentiation mediated by S100A8 and S100A9. Nat Med, 22(3), 288-297.
     
  244. Kaifie A, Kirschner M, Wolf D, Maintz C, Hanel M, Gattermann N, Gokkurt E, Platzbecker U, Hollburg W, Gothert JR, Parmentier S, Lang F, Hansen R, Isfort S, Schmitt K, Jost E, Serve H, Ehninger G, Berd (2016). Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry. J Hematol Oncol, 9, 18-.
     
  245. Kohrs N, Kolodziej S, Kuvardina ON, Herglotz J, Yillah J, Herkt S, Piechatzek A, Salinas Riester G, Lingner T, Wichmann C, Bonig H, Seifried E, Platzbecker U, Medyouf H, Grez M, Lausen J (2016). MiR144/451 Expression Is Repressed by RUNX1 During Megakaryopoiesis and Disturbed by RUNX1/ETO. PLoS Genet, 12(3), 1005946-.
     
  246. Garcia-Manero G, Fenaux P, Al-Kali A, Baer MR, Sekeres MA, Roboz GJ, Gaidano G, Scott BL, Greenberg P, Platzbecker U, Steensma DP, Kambhampati S, Kreuzer KA, Godley LA, Atallah E, Collins R Jr, Kantar (2016). Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial. Lancet Oncol, 17(4), 496-508.
     
  247. Link CS, Teipel R, Heidenreich F, Rucker-Braun E, Schmiedgen M, Reinhardt J, Oelschlagel U, von Bonin M, Middeke JM, Muetherig A, Trautmann-Grill K, Platzbecker U, Bornhauser M, Schetelig J (2016). Durable responses to ibrutinib in patients with relapsed CLL after allogeneic stem cell transplantation. Bone Marrow Transplant, 51(6), 793-798.
     
  248. Garcia-Manero G, Almeida A, Giagounidis A, Platzbecker U, Garcia R, Voso MT, Larsen SR, Valcarcel D, Silverman LR, Skikne B, Santini V (2016). Design and rationale of the QUAZAR Lower-Risk MDS (AZA-MDS-003) trial: a randomized phase 3 study of CC-486 (oral azacitidine) plus best supportive care vs placebo plus best supportive care in patients with IPSS lower-risk myelodysplastic syndromes and poor prognosis due to red blood cell transfusion-dependent anemia and thrombocytopenia. BMC Hematol, 16, 12-.
     
  249. Gortzen J, Hunka LM, Vonnahme M, Praktiknjo M, Kaifie A, Fimmers R, Jansen C, Heine A, Lehmann J, Goethert JR, Gattermann N, Goekkurt E, Platzbecker U, Brossart P, Strassburg CP, Brummendorf TH, Kosch (2016). ?-Glutamyl Transferase Is an Independent Biomarker of Splanchnic Thrombosis in Patients With Myeloproliferative Neoplasm. Medicine (Baltimore), 95(20), 3355-.
     
  250. Borthakur G, Popplewell L, Boyiadzis M, Foran J, Platzbecker U, Vey N, Walter RB, Olin R, Raza A, Giagounidis A, Al-Kali A, Jabbour E, Kadia T, Garcia-Manero G, Bauman JW, Wu Y, Liu Y, Schramek D, Cox (2016). Activity of the oral mitogen-activated protein kinase kinase inhibitor trametinib in RAS-mutant relapsed or refractory myeloid malignancies. Cancer, 122(12), 1871-1879.
     
  251. Kosmider O, Passet M, Santini V, Platzbecker U, Andrieu V, Zini G, Beyne-Rauzy O, Guerci A, Masala E, Balleari E, Bulycheva E, Dreyfus F, Fenaux P, Fontenay M, Park S (2016). Are somatic mutations predictive of response to erythropoiesis stimulating agents in lower risk myelodysplastic syndromes? Haematologica, 101(7), 280-283.
     
  252. Botezatu L, Michel LC, Makishima H, Schroeder T, Germing U, Haas R, van der Reijden B, Marneth AE, Bergevoet SM, Jansen JH, Przychodzen B, Wlodarski M, Niemeyer C, Platzbecker U, Ehninger G, Unnikrish (2016). GFI1(36N) as a therapeutic and prognostic marker for myelodysplastic syndrome. Exp Hematol, 44(7), 590-595.
     
  253. Mossner M, Jann JC, Nowak D, Platzbecker U, Giagounidis A, Gotze K, Letsch A, Haase D, Shirneshan K, Braulke F, Schlenk RF, Haferlach T, Schafhausen P, Bug G, Lubbert M, Ganser A, Busche G, Schuler E, (2016). Prevalence, clonal dynamics and clinical impact of TP53 mutations in patients with myelodysplastic syndrome with isolated deletion (5q) treated with lenalidomide: results from a prospective multicenter study of the german MDS study group (GMDS). Leukemia, 30(9), 1956-1959.
     
  254. Schuler MK, Hornemann B, Pawandenat C, Kramer M, Hentschel L, Beck H, Kasten P, Singer S, Schaich M, Ehninger G, Platzbecker U, Schetelig J, Bornhauser M (2016). Feasibility of an exercise programme in elderly patients undergoing allogeneic stem cell transplantation - a pilot study. Eur J Cancer Care (Engl), 25(5), 839-848.
     
  255. Schuler E, Giagounidis A, Haase D, Shirneshan K, Busche G, Platzbecker U, Nolte F, Gotze K, Schlenk RF, Ganser A, Letsch A, Braulke F, Lubbert M, Bug G, Schafhausen P, Bacher U, Gattermann N, Wulfert (2016). Results of a multicenter prospective phase II trial investigating the safety and efficacy of lenalidomide in patients with myelodysplastic syndromes with isolated del(5q) (LE-MON 5). Leukemia, 30(7), 1580-1582.
     
  256. Eichner R, Heider M, Fernandez-Saiz V, van Bebber F, Garz AK, Lemeer S, Rudelius M, Targosz BS, Jacobs L, Knorn AM, Slawska J, Platzbecker U, Germing U, Langer C, Knop S, Einsele H, Peschel C, Haass C (2016). Immunomodulatory drugs disrupt the cereblon-CD147-MCT1 axis to exert antitumor activity and teratogenicity. Nat Med, 22(7), 735-743.
     
  257. Kaifie A, Isfort S, Gattermann N, Hollburg W, Klausmann M, Wolf D, Maintz C, Hanel M, Goekkurt E, Gothert JR, Platzbecker U, Geer T, Parmentier S, Jost E, Serve H, Ehninger G, Berdel WE, Brummendorf T (2016). Health care setting and severity, symptom burden, and complications in patients with Philadelphia-negative myeloproliferative neoplasms (MPN): a comparison between university hospitals, community hospitals, and office-based physicians. Ann Hematol, 95(9), 1399-1410.
     
  258. Santini V, Almeida A, Giagounidis A, Gropper S, Jonasova A, Vey N, Mufti GJ, Buckstein R, Mittelman M, Platzbecker U, Shpilberg O, Ram R, Del Canizo C, Gattermann N, Ozawa K, Risueno A, MacBeth KJ, Zh (2016). Randomized Phase III Study of Lenalidomide Versus Placebo in RBC Transfusion-Dependent Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes and Ineligible for or Refractory to Erythropoiesis-Stimulating Agents. J Clin Oncol, 34(25), 2988-2996.
     
  259. Mossner M, Jann JC, Wittig J, Nolte F, Fey S, Nowak V, Oblander J, Pressler J, Palme I, Xanthopoulos C, Boch T, Metzgeroth G, Rohl H, Witt SH, Dukal H, Klein C, Schmitt S, Gelss P, Platzbecker U, Bala (2016). Mutational hierarchies in myelodysplastic syndromes dynamically adapt and evolve upon therapy response and failure. Blood, 128(9), 1246-1259.
     
  260. Rauner M, Franke K, Murray M, Singh RP, Hiram-Bab S, Platzbecker U, Gassmann M, Socolovsky M, Neumann D, Gabet Y, Chavakis T, Hofbauer LC, Wielockx B (2016). Increased EPO Levels Are Associated With Bone Loss in Mice Lacking PHD2 in EPO-Producing Cells. J Bone Miner Res, 31(10), 1877-1887.
     
  261. Voelxen N, Wehr C, Gutenberger S, Keller B, Erlacher M, Dominguez-Conde C, Bertele D, Emmerich F, Pantic M, Jennings S, Rakhmanov M, Foerster C, Martens UM, Platzbecker U, Peter HH, Fisch P, Boztug K, (2016). B-cell signaling in persistent polyclonal B lymphocytosis (PPBL). Immunol Cell Biol, 94(9), 830-837.
     
  262. Cremers EM, van Biezen A, de Wreede LC, Scholten M, Vitek A, Finke J, Platzbecker U, Beelen D, Schwerdtfeger R, Volin L, Harhalakis N, Blijlevens N, Nagler A, Kroger N, de Witte T (2016). Prognostic pre-transplant factors in myelodysplastic syndromes primarily treated by high dose allogeneic hematopoietic stem cell transplantation: a retrospective study of the MDS subcommittee of the CMWP of the EBMT. Ann Hematol, 95(12), 1971-1978.
     
  263. Baschant U, Rauner M, Balaian E, Weidner H, Roetto A, Platzbecker U, Hofbauer LC (2016). Wnt5a is a key target for the pro-osteogenic effects of iron chelation on osteoblast progenitors. Haematologica, 101(12), 1499-1507.
     
  264. Petros S (2016). Therapie mit FFP und Faktorenkonzentraten - wie mache ich es richtig? In: Kluge S, Markewitz A, Jorch G, Putensen C, Quintel M, Sybrecht GW, DIVI Jahrbuch 2016/2017 (S. 331-343), Berlin: Medizinische Wissenschaftliche Verlagsgesellschaft.
     
  265. Metze M, Reske A, Petros S (2016). Der blutende Patient. In: Bercker S, Laudi S, Kaisers UX, Intensivmedizin Konkret. (S. 479-494), Köln: Deutsche Ärzteverlag.
     


  266. 2015


  267. Gerloff D, Grundler R, Wurm AA, Brauer-Hartmann D, Katzerke C, Hartmann JU, Madan V, Muller-Tidow C, Duyster J, Tenen DG, Niederwieser D, Behre G (2015). NF-kB/STAT5/miR-155 network targets PU.1 in FLT3-ITD-driven acute myeloid leukemia. Leukemia, 29(3), 535-547.
     
  268. Behrens A, Ell C, Lordick F (2015). Perioperative and Palliative Chemotherapy for Esophageal Cancer. Viszeralmedizin , 31(5), 341-346.
     
  269. Rockstroh A, Al-Ali HK, Lange T, Ponisch W, Krahl R, Cross M, Behre G, Niederwieser D, Pfrepper C (2015). Comparable outcome after single-antigen-mismatched versus matched unrelated donor haematopoietic cell transplantation. J Cancer Res Clin Oncol, 141(12), 2193-2203.
     
  270. Brauer-Hartmann D, Hartmann JU, Wurm AA, Gerloff D, Katzerke C, Verga Falzacappa MV, Pelicci PG, Muller-Tidow C, Tenen DG, Niederwieser D, Behre G (2015). PML/RAR alpha-Regulated miR-181a/b Cluster Targets the Tumor Suppressor RASSF1A in Acute Promyelocytic Leukemia. Cancer Res, 75(16), 3411-3424.
     
  271. Poenisch W, Plotze M, Holzvogt B, Andrea M, Schliwa T, Zehrfeld T, Hammerschmidt D, Schwarz M, Edelmann T, Becker C, Hoffmann FA, Schwarzer A, Kreibich U, Gutsche K, Reifenrath K, Schwarzbach H, Heyn S, Franke GN, Jentzsch M, Leiblein S, Schwind S, Lange T, Vucinic V, AlAli HK, Niederwieser D (2015). Stem cell mobilization and autologous stem cell transplantation after pretreatment with bendamustine, prednisone and bortezomib (BPV) in newly diagnosed multiple myeloma. J Cancer Res Clin Oncol, 141(11), 2013-2022.
     
  272. de Fallois J, Regenthal R, Petros S (2015). Fulminant thrombotic thrombocytopenic purpura (TTP): association with amphetamine consumption? Ann Hematol, 94(2), 337-338.
     
  273. Schneider T, Siegemund T, Siegemund R, Petros S (2015). Thrombin generation and rotational thromboelastometry in the healthy adult population. Hamostaseologie, 35(2), 181-186.
     
  274. Schmidt C, Fingerle-Rowson G, Boehme A, Brendel K, Fischer R, Gonnermann M, Hohler T, Kegel T, Kellermann L, Nusch A, Ponisch W, Wendtner C, Dreyling M (2015). Changes in the diagnosis and treatment of patients with low grade lymphoma in Germany: years 2006-2009. Leuk Lymphoma, 56(3), 694-702.
     
  275. Ludwig H, Rauch E, Kuehr T, Adam Z, Weissmann A, Kasparu H, Autzinger EM, Heintel D, Greil R, Poenisch W, Muldur E, Zojer N (2015). Lenalidomide and dexamethasone for acute light chain-induced renal failure: a phase II study. Haematologica, 100(3), 385-391.
     
  276. Niederwieser C, Kohlschmidt J, Volinia S, Whitman SP, Metzeler KH, Eisfeld AK, Maharry K, Yan P, Frankhouser D, Becker H, Schwind S, Carroll AJ, Nicolet D, Mendler JH, Curfman JP, Wu YZ, Baer MR, Powe (2015). Prognostic and biologic significance of DNMT3B expression in older patients with cytogenetically normal primary acute myeloid leukemia. Leukemia, 29(3), 567-575.
     
  277. Thiel A, Schetelig J, Ponisch W, Schafer-Eckart K, Aulitzky W, Peter N, Schulze A, Maschmeyer G, Neugebauer S, Herbst R, Hanel A, Morgner A, Kroschinsky F, Bornhauser M, Lange T, Wilhelm M, Niederwies (2015). Mito-FLAG with Ara-C as bolus versus continuous infusion in recurrent or refractory AML--long-term results of a prospective randomized intergroup study of the East German Study Group Hematology/Oncology (OSHO) and the Study Alliance Leukemia (SAL). Ann Oncol, 26(7), 1434-1440.
     
  278. Beyer S, Pfrepper C, Kronberg J, Vucinic V, Ziemer M, Simon JC, Niederwieser D, Treudler R (2015). Severe cutaneous necroses and hemorrhagic diathesis in a 73-year-old man. J Dtsch Dermatol Ges, 13(3), 252-255.
     
  279. Vaughn JE, Sorror ML, Storer BE, Chauncey TR, Pulsipher MA, Maziarz RT, Maris MB, Hari P, Laport GG, Franke GN, Agura ED, Langston AA, Rezvani AR, Storb R, Sandmaier BM, Maloney DG (2015). Long-term sustained disease control in patients with mantle cell lymphoma with or without active disease after treatment with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. Cancer, 121(20), 3709-3716.
     
  280. Rockstroh A, Al-Ali HK, Lange T, Ponisch W, Krahl R, Cross M, Behre G, Niederwieser D, Pfrepper C (2015). Comparable outcome after single-antigen-mismatched versus matched unrelated donor haematopoietic cell transplantation. J Cancer Res Clin Oncol, 141(12), 2193-2203.
     
  281. Brauer-Hartmann D, Hartmann JU, Wurm AA, Gerloff D, Katzerke C, Verga Falzacappa MV, Pelicci PG, Muller-Tidow C, Tenen DG, Niederwieser D, Behre G (2015). PML/RAR?-Regulated miR-181a/b Cluster Targets the Tumor Suppressor RASSF1A in Acute Promyelocytic Leukemia. Cancer Res, 75(16), 3411-3424.
     
  282. Poenisch W, Plotze M, Holzvogt B, Andrea M, Schliwa T, Zehrfeld T, Hammerschmidt D, Schwarz M, Edelmann T, Becker C, Hoffmann FA, Schwarzer A, Kreibich U, Gutsche K, Reifenrath K, Schwarzbach H, Heyn (2015). Stem cell mobilization and autologous stem cell transplantation after pretreatment with bendamustine, prednisone and bortezomib (BPV) in newly diagnosed multiple myeloma. J Cancer Res Clin Oncol, 141(11), 2013-2022.
     
  283. Gerloff D, Grundler R, Wurm AA, Brauer-Hartmann D, Katzerke C, Hartmann JU, Madan V, Muller-Tidow C, Duyster J, Tenen DG, Niederwieser D, Behre G (2015). NF-?B/STAT5/miR-155 network targets PU.1 in FLT3-ITD-driven acute myeloid leukemia. Leukemia, 29(3), 535-547.
     


  284. 2014


  285. Koenigsmann M, Casper J, Kahl C, Basara N, Sayer HG, Behre G, Theurich S, Christopeit M, Mohren M, Reichle A, Metzner B, Ganser A, Stadler M, Uharek L, Balleisen L, Hinke A, Hinke R, Niederwieser D (2014). Risk-adapted, treosulfan-based therapy with auto- and allo-SCT for relapsed/refractory aggressive NHL: a prospective phase-II trial. Bone Marrow Transplant, 49(3), 410-415.
     
  286. Jaekel N, Behre G, Behning A, Wickenhauser C, Lange T, Niederwieser D, Al-Ali HK (2014). Allogeneic hematopoietic cell transplantation for myelofibrosis in patients pretreated with the JAK1 and JAK2 inhibitor ruxolitinib. Bone Marrow Transplant, 49(2), 179-184.
     
  287. Hebenstreit K, Iacobelli S, Leiblein S, Eisfeld AK, Pfrepper C, Heyn S, Vucinic V, Franke GN, Krahl R, Fricke S, Becker C, Ponisch W, Behre G, Niederwieser D, Lange T (2014). Low tumor burden is associated with early B-cell reconstitution and is a predictor of favorable outcome after non-myeloablative stem cell transplant for chronic lymphocytic leukemia. Leuk Lymphoma, 55(6), 1274-1280.
     
  288. Fricke S, Hilger N, Fricke C, Schonfelder U, Behre G, Ruschpler P, Boldt A, Oelkrug C, Sack U, Emmrich F (2014). Prevention of graft-versus-host-disease with preserved graft-versus-leukemia-effect by ex vivo and in vivo modulation of CD4(+) T-cells. Cell Mol Life Sci, 71(11), 2135-2148.
     
  289. Ponisch W, Holzvogt B, Plotze M, Andrea M, Bourgeois M, Heyn S, Zehrfeld T, Hammerschmidt D, Schwarz M, Edelmann T, Becker C, Hoffmann FA, Schwarzer A, Kreibich U, Gutsche K, Reifenrath K, Winkelmann C, Krahl R, Remane Y, Hennig E, Schliwa T, Lindner T, Kaiser T, Vucinic V, Behre G, Niederwieser D (2014). Bendamustine and prednisone in combination with bortezomib (BPV) in the treatment of patients with newly diagnosed/untreated multiple myeloma. J Cancer Res Clin Oncol, 140(11), 1947-1956.
     
  290. Eisfeld AK, Schwind S, Hoag KW, Walker CJ, Liyanarachchi S, Patel R, Huang X, Markowitz J, Duan W, Otterson GA, Carson WE 3rd, Marcucci G, Bloomfield CD, de la Chapelle A (2014). NRAS isoforms differentially affect downstream pathways, cell growth, and cell transformation. Proc Natl Acad Sci U S A, 111(11), 4179-4184.
     
  291. Eisfeld AK, Schwind S, Patel R, Huang X, Santhanam R, Walker CJ, Markowitz J, Hoag KW, Jarvinen TM, Leffel B, Perrotti D, Carson WE 3rd, Marcucci G, Bloomfield CD, de la Chapelle A (2014). Intronic miR-3151 within BAALC drives leukemogenesis by deregulating the TP53 pathway. Sci Signal, 7(321), ra36.
     
  292. Whitman SP, Kohlschmidt J, Maharry K, Volinia S, Mrozek K, Nicolet D, Schwind S, Becker H, Metzeler KH, Mendler JH, Eisfeld AK, Carroll AJ, Powell BL, Carter TH, Baer MR, Kolitz JE, Park IK, Stone RM, (2014). GAS6 expression identifies high-risk adult AML patients: potential implications for therapy. Leukemia, 28(6), 1252-1258.
     
  293. Marcucci G, Yan P, Maharry K, Frankhouser D, Nicolet D, Metzeler KH, Kohlschmidt J, Mrozek K, Wu YZ, Bucci D, Curfman JP, Whitman SP, Eisfeld AK, Mendler JH, Schwind S, Becker H, Bar C, Carroll AJ, Ba (2014). Epigenetics Meets Genetics in Acute Myeloid Leukemia: Clinical Impact of a Novel Seven-Gene Score. J Clin Oncol, 32(6), 548-556.
     
  294. Platzbecker U, Al-Ali HK, Gattermann N, Haase D, Janzen V, Krauter J, Gotze K, Schlenk R, Nolte F, Letsch A, Ottmann OG, Kundgen A, Lubbert M, Germing U, Wermke M, Reinhard H, Weiss C, Lieder K, Ehnin (2014). Phase 2 study of oral panobinostat (LBH589) with or without erythropoietin in heavily transfusion-dependent IPSS low or int-1 MDS patients. Leukemia, 28(3), 696-698.
     
  295. Killig M, Friedrichs B, Meisig J, Gentilini C, Bluthgen N, Loddenkemper C, Labopin M, Basara N, Pfrepper C, Niederwieser DW, Uharek L, Romagnani C (2014). Tracking in vivo dynamics of NK cells transferred in patients undergoing stem cell transplantation. Eur J Immunol, 44(9), 2822-2834.
     
  296. Kruger WH, Hirt C, Basara N, Sayer HG, Behre G, Fischer T, Grobe N, Maschmeyer G, Niederwieser D, Dolken G (2014). Allogeneic stem cell transplantation for mantle cell lymphoma--final report from the prospective trials of the East German Study Group Haematology/Oncology (OSHO). Ann Hematol, 93(9), 1587-1597.
     
  297. Becker H, Maharry K, Mrozek K, Volinia S, Eisfeld AK, Radmacher MD, Kohlschmidt J, Metzeler KH, Schwind S, Whitman SP, Mendler JH, Wu YZ, Nicolet D, Paschka P, Powell BL, Carter TH, Wetzler M, Kolitz (2014). Prognostic gene mutations and distinct gene- and microRNA-expression signatures in acute myeloid leukemia with a sole trisomy 8. Leukemia, 28(8), 1754-1758.
     
  298. Federzoni EA, Humbert M, Torbett BE, Behre G, Fey MF, Tschan MP (2014). CEBPA-dependent HK3 and KLF5 expression in primary AML and during AML differentiation. Sci Rep, 4, 4261.
     
  299. Humbert M, Federzoni EA, Britschgi A, Schlafli AM, Valk PJ, Kaufmann T, Haferlach T, Behre G, Simon HU, Torbett BE, Fey MF, Tschan MP (2014). The tumor suppressor gene DAPK2 is induced by the myeloid transcription factors PU.1 and C/EBPalpha during granulocytic differentiation but repressed by PML-RARalpha in APL. J Leukoc Biol, 95(1), 83-93.
     
  300. Eckold J, Poenisch W, Drogies T, Kratzsch J, Teupser D, Thiery J, Bruegel M (2014). Analytical performance and diagnostic potential of immunoassays determining intact immunoglobulin kappa/lambda ratios in monoclonal gammopathies. Clin Lab, 60(9), 1491-1500.
     
  301. Petros S (2014). Direkte Orale Antikoagulantien (DOAK): Management des Blutungsnotfalls. In: Jorch G, Kluge S, Markewitz A, Putensen C, Quintel M, Sybrecht GW, DIVI Jahrbuch 2014/2015. (S. 115-119), Berlin: Medizinisch Wissenscahftliche Verlagsgesellschaft.
     


  302. 2013


  303. Ponisch W, Bourgeois M, Moll B, Heyn S, Jakel N, Wagner I, Rohrberg R, Hurtz HJ, Schmalfeld M, Assmann M, Edelmann T, Mohren M, Hoffmann FA, Becker C, Schwarzer A, Schonfelder U, Zehrfeld T, Hensel G, (2013). Combined bendamustine, prednisone and bortezomib (BPV) in patients with relapsed or refractory multiple myeloma. J Cancer Res Clin Oncol, 139(3), 499-508.
     
  304. Ponisch W, Heyn S, Beck J, Wagner I, Mohren M, Hoffmann FA, Lange T, Schmalfeld M, Zehrfeld T, Schwarzer A, Winkelmann C, Edelmann T, Rohrborn R, Hebenstreit K, Al-Ali HK, Jakel N, Niederwieser D (2013). Lenalidomide, bendamustine and prednisolone exhibits a favourable safety and efficacy profile in relapsed or refractory multiple myeloma: final results of a phase 1 clinical trial OSHO - #077. Br J Haematol, 162(2), 202-209.
     
  305. Ponisch W, Moll B, Bourgeois M, Andrea M, Schliwa T, Heyn S, Schmalfeld M, Edelmann T, Becker C, Hoffmann FA, Schwarzer A, Kreibich U, Egert M, Stiegler R, Krahl R, Remane Y, Bachmann A, Lindner T, Weidhase L, Petros S, Fricke S, Vucinic V, Al Ali H, Niederwieser D (2013). Bendamustine and prednisone in combination with bortezomib (BPV) in the treatment of patients with relapsed or refractory multiple myeloma and light chain-induced renal failure. J Cancer Res Clin Oncol, 139(11), 1937-1946.
     
  306. Katzerke C, Madan V, Gerloff D, Brauer-Hartmann D, Hartmann JU, Wurm AA, Muller-Tidow C, Schnittger S, Tenen DG, Niederwieser D, Behre G (2013). Transcription factor C/EBPα-induced microRNA-30c inactivates Notch1 during granulopoiesis and is downregulated in acute myeloid leukemia. Blood, 122(14), 2433-2442.
     
  307. Goldschmidt H, Kropff M, Mugge LO, Ponisch W (2013). [Therapeutic strategies in multiple myeloma: the future role of bendamustine]. Onkologie, 36(Suppl 1), 19-26.
     
  308. Federzoni EA, Humbert M, Valk PJ, Behre G, Leibundgut EO, Torbett BE, Fey MF, Tschan MP (2013). The actin-binding protein CORO1A is a novel PU.1 (SPI1)- and CEBPA-regulated gene with significantly lower expression in APL and CEBPA-mutated AML patients. Br J Haematol, 160(6), 855-9.
     
  309. Pal P, Kanaujiya JK, Lochab S, Tripathi SB, Sanyal S, Behre G, Trivedi AK (2013). Proteomic analysis of rosiglitazone and guggulsterone treated 3T3-L1 preadipocytes. Mol Cell Biochem, 376(1-2), 81-93.
     
  310. Wang H, Chen P, Wang J, Santhanam R, Aimiuwu J, Saradhi UV, Liu Z, Schwind S, Mims A, Byrd JC, Grever MR, Villalona-Calero MA, Klisovic R, Walker A, Garzon R, Blum W, Chan KK, Marcucci G (2013). In vivo quantification of active decitabine-triphosphate metabolite: a novel pharmacoanalytical endpoint for optimization of hypomethylating therapy in acute myeloid leukemia. AAPS J, 15(1), 242-249.
     
  311. Warneke VS, Behrens HM, Haag J, Balschun K, Boger C, Becker T, Ebert MP, Lordick F, Rocken C (2013). Prognostic and putative predictive biomarkers of gastric cancer for personalized medicine. Diagn Mol Pathol, 22(3), 127-137.
     
  312. Warneke VS, Behrens HM, Boger C, Becker T, Lordick F, Ebert MP, Rocken C (2013). Her2/neu testing in gastric cancer: evaluating the risk of sampling errors. Ann Oncol, 24(3), 725-733.
     
  313. Humbert M, Federzoni EA, Britschgi A, Schlafli AM, Valk PJ, Kaufmann T, Haferlach T, Behre G, Simon HU, Torbett BE, Fey MF, Tschan MP (2013). The tumor suppressor gene DAPK2 is induced by the myeloid transcription factors PU.1 and C/EBPα during granulocytic differentiation but repressed by PML-RARα in APL. J Leukoc Biol, 95(1), 83-93.
     
  314. Lochab S, Pal P, Kapoor I, Kanaujiya JK, Sanyal S, Behre G, Trivedi AK (2013). E3 ubiquitin ligase Fbw7 negatively regulates granulocytic differentiation by targeting G-CSFR for degradation. Biochim Biophys Acta, 1833(12), 2639-2652.
     
  315. Pal P, Lochab S, Kanaujiya JK, Kapoor I, Sanyal S, Behre G, Trivedi AK (2013). E6AP, an E3 ubiquitin ligase negatively regulates granulopoiesis by targeting transcription factor C/EBPα for ubiquitin-mediated proteasome degradation. Cell Death Dis, 4, e590.
     
  316. Pal P, Lochab S, Kanaujiya JK, Kapoor I, Sanyal S, Behre G, Trivedi AK (2013). E3 ubiquitin ligase E6AP negatively regulates adipogenesis by downregulating proadipogenic factor C/EBPalpha. PLoS One, 8(6), e65330.
     
  317. Kanaujiya JK, Lochab S, Kapoor I, Pal P, Datta D, Bhatt ML, Sanyal S, Behre G, Trivedi AK (2013). Proteomic identification of Profilin1 as a corepressor of estrogen receptor alpha in MCF7 breast cancer cells. Proteomics, 13(14), 2100-2112.
     
  318. Kornblit B, Maloney DG, Storb R, Storek J, Hari P, Vucinic V, Maziarz RT, Chauncey TR, Pulsipher MA, Bruno B, Petersen FB, Bethge WA, Hubel K, Bouvier ME, Fukuda T, Storer BE, Sandmaier BM (2013). Fludarabine and 2-Gy TBI is superior to 2 Gy TBI as conditioning for HLA-matched related hematopoietic cell transplantation: a phase III randomized trial. Biol Blood Marrow Transplant, 19(9), 1340-1347.
     
  319. Furst D, Muller C, Vucinic V, Bunjes D, Herr W, Gramatzki M, Schwerdtfeger R, Arnold R, Einsele H, Wulf G, Pfreundschuh M, Glass B, Schrezenmeier H, Schwarz K, Mytilineos J (2013). High-resolution HLA matching in hematopoietic stem cell transplantation: a retrospective collaborative analysis. Blood, 122(18), 3220-3229.
     
  320. Pfeifer H, Wassmann B, Bethge W, Dengler J, Bornhauser M, Stadler M, Beelen D, Vucinic V, Burmeister T, Stelljes M, Faul C, Dreger P, Kiani A, Schafer-Eckart K, Schwerdtfeger R, Lange E, Kubuschok B, (2013). Randomized comparison of prophylactic and minimal residual disease-triggered imatinib after allogeneic stem cell transplantation for BCR-ABL1-positive acute lymphoblastic leukemia. Leukemia, 27(6), 1254-1262.
     
  321. Phillips CL, Davies SM, McMasters R, Absalon M, O'Brien M, Mo J, Broun R, Moscow JA, Smolarek T, Garzon R, Blum W, Schwind S, Marcucci G, Perentesis JP (2013). Low dose decitabine in very high risk relapsed or refractory acute myeloid leukaemia in children and young adults. Br J Haematol, 161(3), 406-410.
     
  322. Marcucci G, Maharry KS, Metzeler KH, Volinia S, Wu YZ, Mrozek K, Nicolet D, Kohlschmidt J, Whitman SP, Mendler JH, Schwind S, Becker H, Eisfeld AK, Carroll AJ, Powell BL, Kolitz JE, Garzon R, Caligiur (2013). Clinical role of microRNAs in cytogenetically normal acute myeloid leukemia: miR-155 upregulation independently identifies high-risk patients. J Clin Oncol, 31(17), 2086-2093.
     
  323. Huang X, Schwind S, Yu B, Santhanam R, Wang H, Hoellerbauer P, Mims A, Klisovic R, Walker AR, Chan KK, Blum W, Perrotti D, Byrd JC, Bloomfield CD, Caligiuri MA, Lee RJ, Garzon R, Muthusamy N, Lee LJ, (2013). Targeted delivery of microRNA-29b by transferrin-conjugated anionic lipopolyplex nanoparticles: a novel therapeutic strategy in acute myeloid leukemia. Clin Cancer Res, 19(9), 2355-2367.
     
  324. Mendler JH, Maharry K, Becker H, Eisfeld AK, Senter L, Mrozek K, Kohlschmidt J, Metzeler KH, Schwind S, Whitman SP, Khalife J, Caligiuri MA, Klisovic RB, Moore JO, Carter TH, Marcucci G, Bloomfield CD (2013). In rare acute myeloid leukemia patients harboring both RUNX1 and NPM1 mutations, RUNX1 mutations are unusual in structure and present in the germline. Haematologica, 98(8), e92.
     
  325. Metzeler KH, Maharry K, Kohlschmidt J, Volinia S, Mrozek K, Becker H, Nicolet D, Whitman SP, Mendler JH, Schwind S, Eisfeld AK, Wu YZ, Powell BL, Carter TH, Wetzler M, Kolitz JE, Baer MR, Carroll AJ, (2013). A stem cell-like gene expression signature associates with inferior outcomes and a distinct microRNA expression profile in adults with primary cytogenetically normal acute myeloid leukemia. Leukemia, 27(10), 2023-2031.
     
  326. Reinhardt J, Flory E, Büttel I, Schröder C, Fricke S, Vucinic V, Cross M, Niederwieser D (2013). MSCs: Clinical Applications and European Regulatory Aspects. In: Hematti P, Keating A, Mesenchymal Stromal Cells: Biology and Clinical Applications (S. 355-364), New York: Humana Press.
     


  327. 2012


  328. Ponisch W, Andrea M, Wagner I, Hammerschmidt D, Kreibich U, Schwarzer A, Zehrfeld T, Schwarz M, Winkelmann C, Petros S, Bachmann A, Lindner T, Niederwieser D (2012). Successful treatment of patients with newly diagnosed/untreated multiple myeloma and advanced renal failure using bortezomib in combination with bendamustine and prednisone. J Cancer Res Clin Oncol, 138(19), 1405-1412.
     
  329. Tschiedel S, Bach E, Jilo A, Wang SY, Lange T, Al-Ali HK, Vucinic V, Niederwieser D, Cross M (2012). Bcr-Abl dependent post-transcriptional activation of NME2 expression is a specific and common feature of chronic myeloid leukemia. Leuk Lymphoma, 53(8), 1569-1576.
     
  330. Petros S, Kliem P, Siegemund T, Siegemund R (2012). Thrombin generation in severe sepsis. Thromb Res, 129(6), 797-800.
     
  331. Lochab S, Pal P, Kanaujiya JK, Tripathi SB, Kapoor I, Bhatt ML, Sanyal S, Behre G, Trivedi AK (2012). Proteomic identification of E6AP as a molecular target of tamoxifen in MCF7 cells. Proteomics, 12(9), 1363-1377.
     
  332. Federmann B, Bornhauser M, Meisner C, Kordelas L, Beelen DW, Stuhler G, Stelljes M, Schwerdtfeger R, Christopeit M, Behre G, Faul C, Vogel W, Schumm M, Handgretinger R, Kanz L, Bethge WA (2012). Haploidentical allogeneic hematopoietic cell transplantation in adults using CD3/CD19 depletion and reduced intensity conditioning: a phase II study. Haematologica, 97(10), 1523-1531.
     
  333. Knofler R, Koscielny J, Tauer JT, Huhn B, Gneuss A, Kuhlisch E, Hofmann A, Petros S, Aumann V, Franke D, Kentouche K, Syrbe G, Seeger K, Haberland H, Klamroth R (2012). Desmopressin testing in haemophilia A patients and carriers: results of a multi centre survey. Hamostaseologie, 32(4), 271-275.
     


  334. 2011


  335. Lange T, Hubmann M, Burkhardt R, Franke GN, Cross M, Scholz M, Leiblein S, Al-Ali HK, Edelmann J, Thiery J, Niederwieser D (2011). Monitoring of WT1 expression in PB and CD34(+) donor chimerism of BM predicts early relapse in AML and MDS patients after hematopoietic cell transplantation with reduced-intensity conditioning. Leukemia, 25(3), 498-505.
     
  336. Al-Ali HK, Bourgeois M, Krahl R, Edel E, Leiblein S, Poenisch W, Basara N, Lange T, Niederwieser D (2011). The impact of the age of HLA-identical siblings on mobilization and collection of PBSCs for allogeneic hematopoietic cell transplantation. Bone Marrow Transplant, 46(11), 1296-1302.
     
  337. Petros S (2011). [Management of bleeding disorders in intensive care medicine]. Med Klin (Munich), 106(3), 177-182.
     
  338. Petros S, Siegemund R (2011). [Thrombin generation in critical illnesses]. Med Klin (Munich), 106(3), 166-170.
     
  339. Sorror ML, Sandmaier BM, Storer BE, Franke GN, Laport GG, Chauncey TR, Agura E, Maziarz RT, Langston A, Hari P, Pulsipher MA, Bethge W, Sahebi F, Bruno B, Maris MB, ... Niederwieser D...Storb R (2011). Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies. JAMA, 306(17), 1874-1883.
     
  340. Keyszer G, Christopeit M, Fick S, Schendel M, Taute BM, Behre G, Muller LP, Schmoll HJ (2011). Treatment of severe progressive systemic sclerosis with transplantation of mesenchymal stromal cells from allogeneic related donors: report of five cases. Arthritis Rheum, 63(8), 2540-2542.
     
  341. Kanaujiya JK, Lochab S, Pal P, Christopeit M, Singh SM, Sanyal S, Behre G, Trivedi AK (2011). Proteomic approaches in myeloid leukemia. Electrophoresis, 32(3-4), 357-367.
     
  342. Sorror ML, Sandmaier BM, Storer BE, Franke GN, Laport GG, Chauncey TR, Agura E, Maziarz RT, Langston A, Hari P, Pulsipher MA, Bethge W, Sahebi F, Bruno B, Maris MB, Yeager A, Petersen FB, Vindelov L, (2011). Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies. JAMA, 306(17), 1874-1883.
     
  343. Rehak M, Meier P, Buhner E, Petros S, Wiedemann P (2011). Occlusion of choroidal vessels in a patient with catastrophic antiphospholipid syndrome. Acta Ophthalmol, 89(6), 595-596.
     


  344. 2010


  345. Braunert L, Bruegel M, Pfrepper C, Thiery J, Niederwieser D (2010). Rituximab in the treatment of acquired haemophilia A in a patient with polymyalgia rheumatica. Hamostaseologie, 30(41), S40-S43.
     
  346. Schlaak M, Schwind S, Wetzig T, Maschke J, Treudler R, Basara N, Lange T, Simon JC, Niederwieser D, Al-Ali HK (2010). UVA (UVA-1) therapy for the treatment of acute GVHD of the skin. Bone Marrow Transplant, 45(12), 1741-48.
     
  347. Schlaak M, Schwind S, Wetzig T, Maschke J, Treudler R, Basara N, Lange T, Simon JC, Niederwieser D, Al-Ali HK (2010). UVA (UVA-1) therapy for the treatment of acute GVHD of the skin. Bone Marrow Transplant, 45(12), 1741-48.
     
  348. Krenauer A, Moll A, Poenisch W, Schmitz N, Niedobitek G, Niederwieser D, Aigner T (2010). EBV-associated post-transplantation B-cell lymphoproliferative disorder following allogenic stem cell transplantation for acute lymphoblastic leukaemia: tumor regression after reduction of immunosuppression - a case report. Diagn Pathol, 5, 21 ff.
     
  349. Bethge WA, Lange T, Meisner C, von Harsdorf S, Bornhaeuser M, Federmann B, Stadler M, Uharek L, Stelljes M, Knop S, Wulf G, Trenschel R, Vucinic V, Dittmann H, Faul C, Vogel W, Kanz L, Bunjes D (2010). Radioimmunotherapy with yttrium-90-ibritumomab tiuxetan as part of a reduced- intensity conditioning regimen for allogeneic hematopoietic cell transplantation in patients with advanced non-Hodgkin lymphoma: results of a phase 2 study. Blood, 116(10), 1795-1802.
     


  350. 2009


  351. Bartsch K, Al-Ali H, Reinhardt A, Franke C, Hudecek M, Kamprad M, Tschiedel S, Cross M, Niederwieser D, Gentilini C (2009). Mesenchymal stem cells remain host-derived independent of the source of the stem-cell graft and conditioning regimen used. Transplantation, 87(2), 217-221.
     
  352. Basara N, Schulze A, Wedding U, Mohren M, Gerhardt A, Junghanss C, Peter N, Dolken G, Becker C, Heyn S, Kliem C, Lange T, Krahl R, Ponisch W, Fricke HJ, Sayer HG, Al-Ali H, Kamprad F, Niederwieser D (2009). Early related or unrelated haematopoietic cell transplantation results in higher overall survival and leukaemia-free survival compared with conventional chemotherapy in high-risk acute myeloid leukaemia patients in first complete remission. Leukemia, 23(4), 635-640.
     
  353. Gyurkocza B, Cao TM, Storb RF, Lange T, Leisenring W, Franke GN, Sorror M, Hoppe R, Maloney DG, Negrin RS, Shizuru JA, Sandmaier BM (2009). Salvage allogeneic hematopoietic cell transplantation with fludarabine and low-dose total body irradiation after rejection of first allografts. Biol Blood Marrow Transplant, 15(10), 1314-1322.
     


  354. 2008


  355. Hudecek M, Bartsch K, Jäkel N, Heyn S, Pfannes R, Al-Ali HK, Cross M, Pönisch W, Gerecke U, Edelmann J, Ittel T, Niederwieser D (2008). Spontaneous remission of acute myeloid leukemia relapse after hematopoietic cell transplantation in a high-risk patient with 11q23/MLL abnormality. Acta Haematol, 119(2), 111-114.
     
  356. Poenisch W, Rozanski M, Goldschmidt H, Hoffmann FA, Boldt T, Schwarzer A, Ritter U, Rohrberg R, Schwalbe E, Uhlig J, Zehrfeld T, Schirmer V, Haas A, Kreibich U, Niederwieser D (2008). Combined bendamustine, prednisolone and thalidomide for refractory or relapsed multiple myeloma after autologous stem-cell transplantation or conventional chemotherapy: results of a Phase I clinical trial. Br J Haematol, 143(2), 191-200.
     
  357. Poenisch W, Rozanski M, Goldschmidt H, Hoffmann FA, Boldt T, Schwarzer A, Ritter U, Rohrberg R, Schwalbe E, Uhlig J, Zehrfeld T, Schirmer V, Haas A, Kreibich U, Niederwieser D (2008). Combined bendamustine, prednisolone and thalidomide for refractory or relapsed multiple myeloma after autologous stem-cell transplantation or conventional chemotherapy: results of a Phase I clinical trial. Br J Haematol, 143(2), 191-200.
     
  358. Kindler S, Siegemund T, Fuhrer D, Petros S (2008). Thrombin generation assay in a patient with acquired factor V inhibitor. J Thromb Haemost, 6(11), 1985-1987.
     
  359. Petros S, Fischer J, Mossner J, Schiefke I, Teich N (2008). Treatment of massive cecal bleeding in a 28-Year-old patient with homozygous factor V deficiency with activated factor VII. Z Gastroenterol, 46(3), 271-273.
     
  360. Petros S (2008). Lepirudin in the management of patients with heparin-induced thrombocytopenia. Biologics, 2(3), 481-490.
     
  361. Schlaak M, Renner R, Treudler R, Harth W, Poenisch W, Kauer F, Grunewald S, Wittekind C, Simon JC (2008). CD30+ anaplastic lymphoma kinase-positive anaplastic large cell lymphoma with an unusual translocation t(11;22). Brit J Dermatol, 159(1), 240-242.
     


  362. 2007


  363. Petros S, Siegemund T, Stolzenburg JU, Siegemund A, Engelmann L (2007). Coagulation monitoring with thrombin generation test during endoscopic extraperitoneal radical prostatectomy for prostate cancer in a patient with severe haemophilia B. Haemophilia, 13(5), 677-679.
     
  364. Winkler J, Muller U, Nenoff P, Seyfarth HJ, Vogtmann M, Borte G, Ponisch W, Kahn T, Wirtz H, Schauer J, Hoheisel G (2007). Treatment of invasive pulmonary aspergillosis in neutropenic patients by additional bronchoscopic amphotericin B instillation. Respiration, 74(6), 663-673.
     
  365. Dargaud Y, Luddington R, Gray E, Negrier C, Lecompte T, Petros S, Hogwood J, Bordet JC, Regnault V, Siegemund A, Baglin T (2007). Effect of standardization and normalization on imprecision of calibrated automated thrombography: an international multicentre study. Br J Haematol, 139(2), 303-309.
     


  366. 2006


  367. Lange T, Franke G, Niederwieser D (2006). Parotitis associated with a parainfluenza virus type 3 infection during aplasia after unrelated allogeneic stem cell transplantation. Leuk Lymphoma, 47(8), 1714-1715.
     
  368. Pönisch W, Niederwieser D (2006). [Late effects after chemotherapy.] Internist (Berl), 47(3), 266-274.
     
  369. Pönisch W, Mitrou PS, Merkle K, Herold M, Assmann M, Wilhelm G, Dachselt K, Richter P, Schirmer V, Schulze A, Subert R, Harksel B, ... Niederwieser D (2006). Treatment of Bendamustine and Prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with Melphalan and Prednisone-a randomized phase III study of the East German Study Group of Hematology and Oncology (OSHO). J Cancer Res Clin Oncol, 132(4), 205-212.
     
  370. Vucinic V, Linck D, Duerr A, Fauser AA, Basara N (2006). Isolated intraperitoneal relapse of AML after allogeneic hematopoietic stem cell transplantation in a patient with extensive chronic GVHD and full donor chimerism in bone marrow. Leuk Lymphoma, 47(8), 1716-1718.
     
  371. Petros S, Siegemund T, Siegemund A, Engelmann L (2006). The effect of different anticoagulants on thrombin generation. Blood Coag Fibrinolysis, 17(2), 131-137.
     
  372. Herold M, Schulze A, Niederwieser D, Franke A, Fricke HJ, Richter P, Freund M, Ismer B, Dachselt K, Boewer C, Schirmer V, Weniger J, Pasold R, Winkelmann C, Klinkenstein C, Schulze M, Arzberger H, Bre (2006). Bendamustine, vincristine and prednisone (BOP) versus cyclophosphamide, vincristine and prednisone (COP) in advanced indolent non-Hodgkins lymphoma and mantle cell lymphoma: results of a randomised phase III trial (OSHO 19). J Cancer Res Clin Oncol, 132(2), 105-112.
     
  373. Bassus S, Wegert W, Krause M, Escuriola-Ettinghausen C, Siegemund A, Petros S, Scholz T, Scharrer I, Kreuz W, Engelmann L, Kirchmaier CM (2006). Platelet-dependent coagulation assays for factor VIII efficacy measurement after substitution therapy in patients with haemophilia A. Platelets, 17(5), 378-84.
     


  374. 2005


  375. Niederwieser D, Cross M, Lange T, Gentilini C, Haffner C, Pönisch W, Raida W, Al-Ali H (2005). Hematopoietic cell transplantation in acute myeloid leukemia. Hematology, 1, 128-132.
     
  376. Niederwieser D, Gentilini C, Hegenbart U, Lange T, Becker C, Wang SY, Bartsch K, Ponisch W, Raida M, Al-Ali H (2005). Allogeneic hematopoietic cell transplantation (HCT) following reduced-intensity conditioning in patients with acute leukemias. Crit Rev Oncol Hematol, 56(2), 275-281.
     
  377. Lange T, Bumm T, Mueller M, Otto S, Al-Ali HK, Grommisch L, Musiol S, Franke C, Krahl R, Niederwieser D, Deininger MW (2005). Durability of molecular remission in chronic myeloid leukemia patients treated with imatinib vs allogeneic stem cell transplantation. Leukemia, 19(7), 1262-1265.
     


  378. 2004


  379. Niederwieser D, Gentilini C, Hegenbart U, Lange T, Moosmann P, Ponisch W, Al-Ali H, Raida M, Ljungman P, Tyndall A, Urbano-Ispizua A, Lazarus HM, Gratwohl A (2004). Transmission of donor illness by stem cell transplantation: should screening be different in older donors? Bone Marrow Transplant, 34, 657-665.
     
  380. Lange T, Deininger M, Brand R, Hegenbart U, Al-Ali H, Krahl R, Poenisch W, Uharek L, Leiblein S, Gentilini C, Petersdorf E, Storb RF, Niederwieser D (2004). BCR-ABL transcripts are early predictors for hematological relapse in chronic myeloid leukemia after hematopoietic cell transplantation with reduced intensity conditioning. Leukemia, 18(9), 1468-1475.
     
  381. Preiss R, Baumann F, Stefanovic D, Niemeyer U, Ponisch W, Niederwieser D (2004). Investigations on the pharmacokinetics of trofosfamide and its metabolites-first report of 4-hydroxy-trofosfamide kinetics in humans. Cancer Chemother Pharmacol, 53(6), 496-502.